Feeds:
Posts
Comments

Archive for the ‘BioTechnology – Venture Creation, Venture Capital’ Category

Original Tweets by @Pharma_BI and by @AVIVA1950 for #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media on June 11, 2018| Leave a Comment »

Original Tweets by @Pharma_BI and by @AVIVA1950 for #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC

Curator: Aviva Lev-Ari, PhD, RN

 

  1.  Jun 6

    More

    ⁦⁩ ⁦⁩ ⁦⁩ in Cambridge study sensors on patients contact dermatitis patients sensors monitor movement text mining sensation reported by patients with sensors trajectory monitored drug device external partnership

  2.  Jun 6

    More

    ⁦⁩ ⁦⁩ ⁦⁩ new drug: Biotech in Scripps, CA and another in Cambridge, MA and ⁦⁩ as Pharma collaboration with biotech Partnership with UPenn with Duke, NC agility in small co scale in Pharma

  3.  Jun 6

    More

    ⁦⁩ ⁦⁩ ⁦⁩ and Medical community decide on directions for surrogate followed by survival NASH redefine NEW drug innovations will move faster Vaccine for NASH growing obesity population Network for collaboration

  4.  Jun 6

    More

    ⁦⁩ immunicity correlated confirm benefit in based study patient to benefit early on while cost benefit be known later inflammatory indicators across diseases JAKS inhibitors which drug for which patient

  5.  Jun 6

    More

    ⁦⁩ ⁦⁩ ⁦⁩ redefine by genomics clinical trials on patients with Gene expression 150 patients 60% improve rate new drug approved in 2011 in oncology how sustain innovation by cost effective trials? Patient selection

  6.  Jun 6

    More

    ⁦⁩ Mikael Dolsten ⁦⁩ R&D budget for contribution capital allocation focus on deep expertise in multiple drugs in multiple indications Lipitor dependence ends patent expiration

  7.  Jun 6

    More

    only by knowing both one can develop applications in vs questions are the hard part vs expertise needed for structural models type of data collected may not be best

    Like

    3

    View Tweet activity

  8.  Jun 6

    More

  9.  Jun 6

    More

    for idiopathic fibrosis using CONNECTION OF DRUG AND DISEASE known after development, pharma needs that BEFORE a drug is developed, clinics based on BRCA for treatment, finding binding targets/drug

    1 reply2 retweets3 likes
    Reply

    1

    Retweet

    2

    Like

    3

    View Tweet activity

  10.  Jun 6

    More

    for patients goals apply right approach to care right drug respond to therapy is a HC goal combined with patient goals

  11.  Jun 6

    More

    @FoundationMedicine in 7 days genomic data, clinical data and patient of patient took place in clean data sets are a must for patient total clinical profile

    Retweet

    1

    Like

    3

  12.  Jun 6

    More

    COHORT is assisted by for clinical trials of rare types of cancers on small population of patients. Synthetic data compared with observed data for can get wrong results by using

    1 retweet1 like
    Retweet

    1

    Like

    1

  13.  Jun 6

    More

    @FoundationMedicine sequenced 200,000 Cancer patients genome use data to Target positive predicted responders to accelerate clinical trials. use of on genomic data for

  14.  Jun 6

    More

    -based value in leadership is brief the dime

  15.  Jun 6

    More

    #@AVIVA1950 to launch an industry stick initiative

  16.  Jun 6

    More

    2008

  17.  Jun 5

    More

    Breakthrough , June 5, 2018 , Boston, BCEC via

  18.  Jun 5

    More

    -Making and of the : Findings from , June 5, 1:45-2:45PM, BIO 2018!, Boston, BCEC via

  19.  Jun 5

    More

    @KatrineBosley @EditasMedicine Valuation for 23andme? Each pool of capital has different investors been attracted

  20.  Jun 5

    More

    @JohnMaraganore @ALNYLAMPHARMACEUTICALS In 16 years rained $4Billion and expenses $2.5Billion – still not profitable – that what it takes

  21.  Jun 5

    More

    @JeanFrancisFormela Science is extraordinary A lot of capital and very many tech ventures over supply of capital accelerates the business More capital is better, what to invest is critical

  22.  Jun 5

    More

    & , June 5, 11-12, BIO 2018! Boston, BCEC via

  23.  Jun 5

    More

    US is not the only player, CANADA’ universal payer system made major strides lung cancer experienced development of 50 drug base on tumor type predict likelihood drug resistance BR CA patient which not require therapy

  24.  Jun 5

    More

    @RajuKucherlapati Integration of EMR Partners leader missing link is integration of Genomic dat aat the patient level with clinical dat of patients Patients will manage their 23andme data PM is global vs access to care

  25.  Jun 5

    More

    @RajuKucherlapati with million of people with genetic and medical information — searches of profile too group patients for optimal of with DB of – IBM

  26.  Jun 5

    More

    @RajuKucherlapati Detection at pre-natal stages of multiple fetal disorders, abnormality, diagnosis drive treatment – genetic testing critical in cost Cardiomayopaty: in Young athlete genetic disorder

    Like

    2

  27.  Jun 5

    More

    Sajeev Kohli (11th Grade, Waterloo, On, Canada)Receives Top Honor at International BioGENEius Challenge Students from California, Washington and Germany named runners-up June 5, 2018 – Boston, Massachusetts –

  28.  Jun 5

    More

    : based Systems, June 5, BIO 2018!, Boston, BCEC via

    1 like

    Like

    1

  29.  Jun 4

    More

    Tales from the – Four Unique Approaches to Turning into via

  30.  Jun 4

    More

    with , MD, President, Novartis Institutes for Biomedical Research (NIBR) ! via

    1 retweet
    Retweet

    1

  31.  Jun 4

    More

    June 4, 2018 – and , BIO 2018! at Boston BCEC via

    2 likes
    Like

    2

  32.  Jun 4

    More

    @TimothyBelski Joint Program Executive Office for Chemical and Biological Defense Manufacturing for DoD Infrastructure to manage across Government RFP Process

  33.  Jun 3

    More

    We cover this event in Real Time

    1 like

    Like

    1

  34.  Jun 3

    More

    Aviva Lev-Ari Retweeted MassBio

    BRAVO MA the of

    Aviva Lev-Ari added,

    It’s no wonder is in Massachusetts next week. Great things are happening here for the economy and for patients.
    1 like

    Like

    1

  35.  Jun 3

    More

    Aviva Lev-Ari Retweeted JNJ Innovation

    Interested Chief Scientific Officer

    Aviva Lev-Ari added,

    Mark your calendars! Chief Scientific Officer Paul Stoffels will sit down with founder on Monday at 4pm at to discuss how we can speed innovation in science and…

Read Full Post »

Re-Tweets and Likes by @Pharma_BI @AVIVA1950 from #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media on June 11, 2018| Leave a Comment »

Re-Tweets and Likes by @Pharma_BI and by @AVIVA1950 from #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC

Curator: Aviva Lev-Ari, PhD, RN

 

  1.   Retweeted

     Jun 7

    More

    Aviva Lev-Ari Retweeted Jeff Galvin

    Well put I agree with you, Jeff

    Aviva Lev-Ari added,

    Congratulations for an impactful conference! You brought together the brightest national and international industry minds to advance . I look forward to !
    0 replies1 retweet1 like
    Reply
    Retweeted

    1

    Liked

    1

    View Tweet activity
  2.   Retweeted

     Jun 7

    More

    Aviva Lev-Ari Retweeted I Am Biotech

    For see

    Aviva Lev-Ari added,

    Understanding the Voice: Unique Perspectives on
    0 replies1 retweet1 like
    Reply
    Retweeted

    1

    Liked

    1

    View Tweet activity

  3.  Jun 7

    More

    News Release Makes History in  – , and highlights via

    https://twitter.com/i/cards/tfw/v1/1004938263482847234?cardname=summary&autoplay_disabled=true&forward=true&earned=true&edge=true&lang=en&card_height=130&scribe_context=%7B%22client%22%3A%22web%22%2C%22page%22%3A%22me%22%2C%22section%22%3A%22profile%22%2C%22component%22%3A%22tweet%22%7D&bearer_token=AAAAAAAAAAAAAAAAAAAAAPYXBAAAAAAACLXUNDekMxqa8h%252F40K4moUkGsoc%253DTYfbDKbT3jJPCEVnMYqilB28NHfOPqkca3qaAxGfsyKCs0wRbw#xdm_e=https%3A%2F%2Ftwitter.com&xdm_c=default5891&xdm_p=1
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  4.  Jun 7

    More

    Aviva Lev-Ari Retweeted Christiane Truelove

    BRAVO FDA in 2018 is AGILE

    Aviva Lev-Ari added,

    RT : Under companies have no obligation to honor requests. But some ppl think they do, and exchanges like this could become more common. …
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  5.  Jun 7

    More

    Aviva Lev-Ari Retweeted CCAB

    ASCO weigh in on CAR-Ts versus bispecific antibodies

    Aviva Lev-Ari added,

    Experts at BIO, ASCO weigh in on CAR-Ts versus bispecific antibodies
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  6.  Jun 7

    More

    Aviva Lev-Ari Retweeted Dana-Farber News

    Aviva Lev-Ari added,

    Dana-Farber President and CEO Dr. Laurie Glimcher shares her views on the state of , treatment, and care at .
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity
  7.   Retweeted

     Jun 7

    More

    🇬🇧 has >5600 LifeSci businesses. Find cos w/ solutions for your business in our 🇬🇧 BioPharma asset list

    https://twitter.com/i/cards/tfw/v1/1004763844831563776?cardname=summary_large_image&autoplay_disabled=true&forward=true&earned=true&edge=true&lang=en&card_height=344&scribe_context=%7B%22client%22%3A%22web%22%2C%22page%22%3A%22me%22%2C%22section%22%3A%22profile%22%2C%22component%22%3A%22tweet%22%7D&bearer_token=AAAAAAAAAAAAAAAAAAAAAPYXBAAAAAAACLXUNDekMxqa8h%252F40K4moUkGsoc%253DTYfbDKbT3jJPCEVnMYqilB28NHfOPqkca3qaAxGfsyKCs0wRbw#xdm_e=https%3A%2F%2Ftwitter.com&xdm_c=default5892&xdm_p=1
    0 replies2 retweets3 likes
    Reply
    Retweeted

    2

    Liked

    3

    Direct message

  8.  Jun 7

    More

    Aviva Lev-Ari Retweeted Jim Greenwood

    BRAVO inaugural Henri A. Termeer Biotechnology Visionary Award

    Aviva Lev-Ari added,

    It was my pleasure to present with the inaugural Henri A. Termeer Biotechnology Visionary Award.
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  9.  Jun 7

    More

    Aviva Lev-Ari Retweeted JNJ Innovation

    BRAVO

    Aviva Lev-Ari added,

    LIVE from the session with ‘s who is “looking for communities that are interested about plugging in and being truly ” to foster & to…
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity
  10.   Retweeted

     Jun 7

    More

    The 2018 Bio International Convention has been amazing! This was the view from our water taxi ride to the hotel last night! 🚤🛳🛥⛵️

    0 replies1 retweet1 like
    Reply
    Retweeted

    1

    Liked

    1

    Direct message

  11.  Jun 7

    More

    Aviva Lev-Ari Retweeted Ozmosi

    TRUE

    Aviva Lev-Ari added,

    : Depression, Pain Drug Developers Starve for Dollars as Companies Feast
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity
  12.   Retweeted

     Jun 7

    More

    On this last day of , want to hear from you! What was your favorite part of this year?

    https://twitter.com/i/cards/tfw/v1/1004793829168504833?cardname=poll4choice_text_only&autoplay_disabled=true&forward=true&earned=true&edge=true&lang=en&card_height=184&scribe_context=%7B%22client%22%3A%22web%22%2C%22page%22%3A%22me%22%2C%22section%22%3A%22profile%22%2C%22component%22%3A%22tweet%22%7D&bearer_token=AAAAAAAAAAAAAAAAAAAAAPYXBAAAAAAACLXUNDekMxqa8h%252F40K4moUkGsoc%253DTYfbDKbT3jJPCEVnMYqilB28NHfOPqkca3qaAxGfsyKCs0wRbw#xdm_e=https%3A%2F%2Ftwitter.com&xdm_c=default5893&xdm_p=1
    0 replies2 retweets3 likes
    Reply
    Retweeted

    2

    Like

    3

    Direct message

  13.  Jun 7

    More

    Aviva Lev-Ari Retweeted Sanofi US

    BRAVO Sanofi

    Aviva Lev-Ari added,

    Through Sanofi Ventures, the corporate VC arm of Sanofi, we build strong relationships with innovators and entrepreneurs to develop future strategic collaborations and, ultimately, realize cutting-edge treatments for…
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  14.  Jun 7

    More

    Aviva Lev-Ari Retweeted Sue Desmond-Hellmann

    HEROS for cure

    Aviva Lev-Ari added,

    This quote from the late Henri Termeer explains why I nearly couldn’t finish my 2 minute acceptance speech for the inaugural Henri A. Termeer Biotech Visionary Award without bursting into tears. ⁦⁩
    0 replies1 retweet1 like
    Reply
    Retweet

    1

    Like

    1

    View Tweet activity

  15.  Jun 7

    More

    Aviva Lev-Ari Retweeted BIO Intl Convention

    BRAVO

    Aviva Lev-Ari added,

    That’s a wrap, folks! Thanks to attendees, exhibitors, sponsors, volunteers, staff members, contractors, and for another record breaking year! We really did MAKE HISTORY and…
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  16.  Jun 7

    More

    Aviva Lev-Ari Retweeted Noy Kaufman

    Aviva Lev-Ari added,

    Had such a great time at the  convention in Boston!  Learned so much about entrepreneurship in biotech through the National Science Foundation (NSF) I-CORPS program, Massachusetts Institute of Technology venture mentoring, and UNHInnovation. We co……
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  17.  Jun 7

    More

    Aviva Lev-Ari Retweeted Business Sweden Invest

    Aviva Lev-Ari added,

    Five Swedish hot spots for precision medicine development in Sweden. Find out how you can tap in to the Swedish landscape. Looking for something to bring home from ? Download…
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  18.  Jun 7

    More

    Aviva Lev-Ari Retweeted Alaric DeArment

    Aviva Lev-Ari added,

    You’ve heard about the sky-high response rates, but clinical competence and infrastructure remain two big challenges ahead for therapies. …
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  19.  Jun 7

    More

    Aviva Lev-Ari Retweeted Mike Huckman

    BRAVO

    Aviva Lev-Ari added,

    Here’s on ways to make progress in the fight against opioid addiction. “Buzz Center” via
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  20.  Jun 7

    More

    Aviva Lev-Ari Retweeted JNJ Innovation

    BRAVO

    Aviva Lev-Ari added,

    Congratulations we certainly had a few of those meetings
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  21.  Jun 7

    More

    Aviva Lev-Ari Retweeted Elizabeth Cutler

    Bravo

    Aviva Lev-Ari added,

    If you enjoyed but want more applications for info, come back to Boston in October. Registration is now open:
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  22.  Jun 7

    More

    Aviva Lev-Ari Retweeted Sanofi US

    BRAVO Sanofi, so smart to have bought Genzyme

    Aviva Lev-Ari added,

    Rachel Sha, VP Digital BD & Licensing, during today’s New Tech & Digital Advances for Drug Discovery session: “Big pharma doesn’t typically like to take big risks… We look for partners who are focused on details and…
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  23.  Jun 7

    More

    Aviva Lev-Ari Retweeted Biotech Institute

    BRAVO Challenge!

    Aviva Lev-Ari added,

    This video will “Blow your Mind.” Congratulations, Sajeev Kohli for winning then2018 International Challenge!
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  24.  Jun 7

    More

    Aviva Lev-Ari Retweeted IAM Platform

    Aviva Lev-Ari added,

    IAM Platform Curated Retweet: Via: …
    0 replies1 retweet1 like
    Reply
    Retweet

    1

    Like

    1

    View Tweet activity

  25.  Jun 7

    More

    Aviva Lev-Ari Retweeted Sema4

    and at

    Aviva Lev-Ari added,

    Our CEO Dr Eric Schadt discussing how to extract signal from the noise of sets, using and at
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  26.  Jun 7

    More

    Aviva Lev-Ari Retweeted Worldwide Clinical

    are changing

    Aviva Lev-Ari added,

    Take uncommon pics like this using our giveaway. At Booth 2654, you can meet with our experts & hear how our approach can help your .
    0 replies0 retweets1 like
    Reply
    Retweet

    Like

    1

    View Tweet activity

  27.  Jun 7

    More

    Aviva Lev-Ari Retweeted Lori Collins

    ‘Largest Business Partnering Event’! Proud to cover the event in

    Aviva Lev-Ari added,

    Yesterday, made history by setting a GUINNESS WORLD RECORD for the ‘Largest Business Partnering Event’!  is proud to be a part of
    0 replies0 retweets1 like
    Reply
    Retweet

    Like

    1

    View Tweet activity

  28.  Jun 7

    More

    Aviva Lev-Ari Retweeted Mike Huckman

    BRAVO One HUGE man

    Aviva Lev-Ari added,

    Here’s CEO and Board Chair talking about a big year for his company & at the “Buzz Center” via
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  29.  Jun 7

    More

    Aviva Lev-Ari Retweeted Cleveland Scott York

    45,000 Partening sessions – BRAVO !!

    Aviva Lev-Ari added,

    CSYer Hazel set a world record (with a little help from her friends) by being part of the breaking partnering event that was
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  30.  Jun 7

    More

    Aviva Lev-Ari Retweeted Thermo Fisher G.R.

    BRAVO gravitas

    Aviva Lev-Ari added,

    Congrats & on hosting a wicked great ! That’s a wrap.
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  31.  Jun 7

    More

    Aviva Lev-Ari Retweeted The Global IP Center

    KEY in see our

    Aviva Lev-Ari added,

    🔍
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  32.  Jun 7

    More

    Aviva Lev-Ari Retweeted NHS Research Scotland

    BRAVO Scotland in

    Aviva Lev-Ari added,

    Thank you – building and to help make a positive difference to within , the and internationally – thank you for…
    0 replies0 retweets2 likes
    Reply
    Retweet

    Liked

    2

    View Tweet activity

  33.  Jun 7

    More

    Aviva Lev-Ari Retweeted Quanterix

    BRAVO landscape in in light of

    Aviva Lev-Ari added,

    Great segments from on the landscape in in light of . We’re proud to be among the companies helping to further innovation and achievement in the hub!
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  34.  Jun 7

    More

    Aviva Lev-Ari Retweeted Vanitha Sekar

    made by Bill & Melinda Gates Medical Research Institution most nobel cause

    Aviva Lev-Ari added,

    Fireside chat at with Sue Desmond-Hellmann, Susan Windham-Bannister & Penny Heaton about the Bill & Melinda Gates Medical Research Institution & their aim to translate innovative discoveries into solutions to…
    0 replies0 retweets1 like
    Reply
    Retweet

    Like

    1

    View Tweet activity

  35.  Jun 7

    More

    Aviva Lev-Ari Retweeted HLC

    in Medicine

    Aviva Lev-Ari added,

    RT : See how we’re using tools used in facial recognition to speed up .
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  36.  Jun 7

    More

    Aviva Lev-Ari Retweeted BlueCloud

    BRAVO Argentine

    Aviva Lev-Ari added,

    Our 1st and we had a blast! The experience was so unique and promising. Let’s create a better world, together.
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  37.  Jun 7

    More

    Aviva Lev-Ari Retweeted NFIA North America

    BRAVO Holland! places Holland No. 1 in the world for medical technology patents!

    Aviva Lev-Ari added,

    The ’ world-class and highly collaborative sector places Holland No. 1 in the world for medical technology patents. Learn more about healthcare innovation: …
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  38.  Jun 7

    More

    Aviva Lev-Ari Retweeted Intract Pharma

    Amazing COnference

    Aviva Lev-Ari added,

    Thanks for having us!
    0 replies0 retweets1 like
    Reply
    Retweet

    Like

    1

    View Tweet activity

  39.  Jun 7

    More

    Aviva Lev-Ari Retweeted MacBioCom

    BRAVO

    Aviva Lev-Ari added,

    Fascinating panel discussion this morning and a happy birthday (belated) to
    0 replies0 retweets1 like
    Reply
    Retweet

    Like

    1

    View Tweet activity

  40.  Jun 7

    More

    Aviva Lev-Ari Retweeted Hassan Naqvi

    meets INDUSTRY: BIOTECH & PHARMA with success

    Aviva Lev-Ari added,

    Great seeing so many colleagues great partnering as part of the Academic Zone. See you all in 2019!
    1 reply0 retweets1 like
    Reply

    1

    Retweet

    Like

    1

    View Tweet activity

  41.  Jun 7

    More

    Aviva Lev-Ari Retweeted IN-PART

    INDEED, the best conference I have attended since 2013 when I cover in Real Time conferences as

    Aviva Lev-Ari added,

    And that’s a wrap – what a week for ! Welcome to our new IN-PART’ners & thank you for a great event! (Source: Rene Schwietzke / CC2)
    0 replies0 retweets1 like
    Reply
    Retweet

    Like

    1

    View Tweet activity

  42.  Jun 7

    More

    Aviva Lev-Ari Retweeted JNJ Innovation

    BRAVO J&J for your broad spectrum in

    Aviva Lev-Ari added,

    0:47
    is almost over & what a week it has been! We broke a record, forged new & celebrated 25 years of . Here’s to another 25 years of , & life-changin…
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  43.  Jun 7

    More

    Aviva Lev-Ari Retweeted Penny Heaton

    MOST NOBEL cause by MRI can be a catalyst to address urgent global health

    Aviva Lev-Ari added,

    Enjoyed sharing how the Gates MRI can be a catalyst to address urgent global health challenges in TB, malaria, and diarrheal diseases
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  44.  Jun 7

    More

    Aviva Lev-Ari Retweeted I Am Biotech

    bRAVO I Am Biotech

    Aviva Lev-Ari added,

    , and Future Day: Drives
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  45.  Jun 7

    More

    Aviva Lev-Ari Retweeted ARMI

    BRAVO Aussi

    Aviva Lev-Ari added,

    And that’s a wrap. After 4 invigorating days, has been a huge success. A special thank you to for being there & to the Australian delegation including …
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity
  46.   Retweeted

     Jun 7

    More

    Fireside chat with at

    0 replies1 retweet1 like
    Reply
    Retweeted

    1

    Liked

    1

    Direct message
  47.   Retweeted

     Jun 6

    More

    Jeff Galvin, CEO of Rockville-based presented his company’s innovations in therapies for HIV, phenylketonuria, and cancer at . After the presentation, he was mobbed by potential investors and partners!

    2 replies8 retweets14 likes
    Reply

    2

    Retweeted

    8

    Liked

    14

    Direct message
  48.   Retweeted

     Jun 6

    More

    How do you schedule hundreds of meetings all at once? has it figured out. Meeting many great potential supporters.

    0 replies6 retweets7 likes
    Reply
    Retweeted

    6

    Liked

    7

    Direct message
  49.   Retweeted

     Jun 6

    More

    It doesn’t get more epic than this l! The QUEEN, DIANA ROSS!

    0 replies6 retweets25 likes
    Reply
    Retweeted

    6

    Liked

    25

    Direct message
  50.   Retweeted

     Jun 5

    More

    Absolutely inspiring group of advocates on the patient voice panel. I feel honored to be in the room with them, listening to their remarkable stories and insights.

    0 replies6 retweets15 likes
    Reply
    Retweeted

    6

    Liked

    15

    Direct message
  51.   Retweeted

     Jun 6

    More

    Board of Directors Chair on diversity in during his Fireside Chat

    0 replies14 retweets8 likes
    Reply
    Retweeted

    14

    Liked

    8

    Direct message
  52.   Retweeted

     Jun 4

    More

    And for more on-the-ground analysis while you’re at , sign up for our daily newsletter, BIO in 30 Seconds.

    0 replies3 retweets5 likes
    Reply
    Retweeted

    3

    Liked

    5

    Direct message
    Show this thread
  53.   Retweeted

     Jun 4

    More

    THURSDAY: (yes, twice!), 9:00am, 259B, on biotech’s data tsunami

    1 reply1 retweet3 likes
    Reply

    1

    Retweeted

    1

    Liked

    3

    Direct message
    Show this thread
  54.   Retweeted

     Jun 4

    More

    TUESDAY: , 4:15pm, 259A, on a new era of biotech journalism

    1 reply3 retweets5 likes
    Reply

    1

    Retweeted

    3

    Liked

    5

    Direct message
    Show this thread
  55.   Retweeted

     Jun 4

    More

    TUESDAY: , 1:45pm, 210B, on how to apply the lessons of immunotherapy from cancer to other diseases.

    1 reply9 retweets20 likes
    Reply

    1

    Retweeted

    9

    Liked

    20

    Direct message
    Show this thread
  56.   Retweeted

     Jun 4

    More

    MONDAY: , 4:00pm, 210A, talking how to cut waste between big pharma and payers in precision medicine.

    1 reply2 retweets4 likes
    Reply

    1

    Retweeted

    2

    Liked

    4

    Direct message
    Show this thread
  57.   Retweeted

     Jun 4

    More

    MONDAY: , 1:00pm, 206AB, talking what drug hunters look for in early stage assets.

    1 reply1 retweet6 likes
    Reply

    1

    Retweeted

    1

    Liked

    6

    Direct message
    Show this thread
  58.   Retweeted

     Jun 4

    More

    MONDAY: , 12:30pm at , talking best practices for co-working in the life sciences. (From the archives)

    1 reply8 retweets12 likes
    Reply

    1

    Retweeted

    8

    Liked

    12

    Direct message
    Show this thread
  59.   Retweeted

     Jun 4

    More

    THREAD: STAT is all over . Here’s where to find us.

    2 replies10 retweets16 likes
    Reply

    2

    Retweeted

    10

    Liked

    16

    Direct message
    Show this thread
  60.   Retweeted

     Jun 4

    More

    speaking with the member delegation at We’ve come to share with the world the excellence of our life science community in Canada.

    0 replies10 retweets24 likes
    Reply
    Retweeted

    10

    Liked

    24

    Direct message
  61.   Retweeted

     Jun 3

    More

    Team Queensland ready to showcase our state’s fantastic capabilities in all things biotech in Boston

    , ,  and 4 others
    3 replies37 retweets92 likes
    Reply

    3

    Retweeted

    37

    Liked

    92

    Direct message
  62.   Retweeted

     Jun 3

    More

    kicks off tomorrow in Boston, MA. Dr Glenn Begley, CEO and Linda Peterson, COO will be attending. DM us if you would like to connect with them.

    1 reply4 retweets20 likes
    Reply

    1

    Retweeted

    4

    Liked

    20

    Direct message
  63.   Retweeted

     Jun 4

    More

    Heading to my first BIO convention, the rain can’t stop my excitement! 😁

    2 replies7 retweets33 likes
    Reply

    2

    Retweeted

    7

    Liked

    33

    Direct message
  64.   Retweeted

     Jun 4

    More

    Proud to sponsor . We at love supporting and their missions to improve our health! See you at as we keep the startup celebration going tomorrow night! BIOGA25 for $25 GA tix

    , ,  and 3 others
    0 replies11 retweets28 likes
    Reply
    Retweeted

    11

    Liked

    28

    Direct message
  65.   Retweeted

     Jun 1

    More

    Our friends at have put together the ultimate guide to the (). It features a complete list of conferences, private events/receptions, plus much more, all happening throughout the week. Get it here >>

    0 replies4 retweets14 likes
    Reply
    Retweeted

    4

    Liked

    14

    Direct message
  66.   Retweeted

     Jun 6

    More

    Through Pfizer Ventures, we plan to invest $600M in innovative science, with approximately $150M specifically targeted toward neuroscience. Join us at to learn more:

    3 replies26 retweets69 likes
    Reply

    3

    Retweeted

    26

    Liked

    69

    Direct message
  67.   Retweeted

     Jun 4

    More

    “It will take you 10-15 years to get a breakthrough, but if you don’t start, you’ll never get there,” says J&J’s CSO Paul Stoffels when asked about at – at Boston Convention & Exhibition Center

    ,  and 
    0 replies14 retweets31 likes
    Reply
    Retweeted

    14

    Liked

    31

    Direct message
  68.   Retweeted

     Jun 5

    More

    Well done

    2 replies5 retweets31 likes
    Reply

    2

    Retweeted

    5

    Liked

    31

    Direct message
  69.   Retweeted

     Jun 4

    More

    Great Q on driving (innovation in) “Huge opportunity in partnering with Pharma, not in replacing them, mainly due to the complexity of ”

    0 replies10 retweets23 likes
    Reply
    Retweeted

    10

    Liked

    23

    Direct message
  70.   Retweeted

     Jun 1

    More

    Penny Heaton Retweeted BIO Intl Convention

    Looking forward to next week, where we’ll have the opportunity to formally introduce the Gates MRI and share the mission, vision, and values behind the work we’re doing to accelerate product development for diseases that disproportionately affect the world’s poorest.

    Penny Heaton added,

    While you’re still connected to your home or company’s wi-fi, download the myBIO event planning app for ! Browse speakers, sessions, events and exhibitors, and add the ones you want to see to your…
    0 replies17 retweets44 likes
    Reply
    Retweeted

    17

    Liked

    44

    Direct message
  71.   Retweeted

     Jun 4

    More

    Attending ? These SECRET STAIRS, only minutes from the convention center, lead to our local Fort Point restos, breweries and more!

    1 reply8 retweets46 likes
    Reply

    1

    Retweeted

    8

    Liked

    46

    Direct message
  72.   Retweeted

     Jun 1

    More

    I got the numbers on the gender diversity of the speaker roster at , after a packed full of Michaels

    https://twitter.com/i/cards/tfw/v1/1002564069193277440?cardname=summary_large_image&autoplay_disabled=true&forward=true&earned=true&edge=true&lang=en&card_height=344&scribe_context=%7B%22client%22%3A%22web%22%2C%22page%22%3A%22me%22%2C%22section%22%3A%22profile%22%2C%22component%22%3A%22tweet%22%7D&bearer_token=AAAAAAAAAAAAAAAAAAAAAPYXBAAAAAAACLXUNDekMxqa8h%252F40K4moUkGsoc%253DTYfbDKbT3jJPCEVnMYqilB28NHfOPqkca3qaAxGfsyKCs0wRbw#xdm_e=https%3A%2F%2Ftwitter.com&xdm_c=default5894&xdm_p=1
    5 replies23 retweets50 likes
    Reply

    5

    Retweeted

    23

    Like

    50

    Direct message
  73.   Retweeted

     Jun 5

    More

    At … it’s like Epcot in here! So many countries and states courting the bio biz.

    2 replies10 retweets37 likes
    Reply

    2

    Retweeted

    10

    Liked

    37

    Direct message
  74.   Retweeted

     Jun 6

    More

    the best way to conclude this incredible !!!

    1 reply4 retweets20 likes
    Reply

    1

    Retweeted

    4

    Liked

    20

    Direct message
  75.   Retweeted

     Jun 3

    More

    Making History in Boston.

    1 reply19 retweets78 likes
    Reply

    1

    Retweeted

    19

    Liked

    78

    Direct message
  76.   Retweeted

     Jun 4

    More

    At biggest biopharma partnering event in the world, scale is pretty amazing…

    0 replies8 retweets55 likes
    Reply
    Retweeted

    8

    Liked

    55

    Direct message
  77.   Retweeted

     Jun 4

    More

    I can’t believe attendees are told by conference organizers that “locals” recommend: “Let loose and explore the nightlife of Boston, grab a couple beers at the iconic “Cheers” bar.” Let me qualify that: NOBODY IN THIS CITY WOULD RECOMMEND THAT.

    7 replies31 retweets184 likes
    Reply

    7

    Retweeted

    31

    Liked

    184

    Direct message
    Show this thread
  78.   Retweeted

     Jun 5

    More

    How cool is this new tool from ?! It provides info on partnering opportunities and contacts for over 60+ patient advocacy groups. Very useful!

    1 reply16 retweets48 likes
    Reply

    1

    Retweeted

    16

    Liked

    48

    Direct message
  79.   Retweeted

     Jun 4

    More

    And here it is, the most famous Paul Stoffels quote we hear ALL THE TIME at “You take the risk and I take the blame” in

    , ,  and 7 others
    4 replies32 retweets97 likes
    Reply

    4

    Retweeted

    32

    Liked

    97

    Direct message
  80.   Retweeted

     Jun 6

    More

    We MADE GUINNESS HISTORY!

    3 replies53 retweets136 likes
    Reply

    3

    Retweeted

    53

    Liked

    136

    Direct message
  81.   Retweeted

     Jun 6

    More

    . – tonight, Karl-Rudolf Erlemann of was all of us.

    0 replies3 retweets6 likes
    Reply
    Retweeted

    3

    Liked

    6

    Direct message
  82.   Retweeted

     Jun 7

    More

    Which biopharmaceutical companies are making a real difference for patients? Our CSO Michael Severino explains how to spot R&D leaders.

    1 reply6 retweets16 likes
    Reply

    1

    Retweeted

    6

    Liked

    16

    Direct message
  83.   Retweeted

     Jun 6

    More

    Had to get to the front row for the encore at live!

    0 replies3 retweets11 likes
    Reply
    Retweeted

    3

    Liked

    11

    Direct message
  84.   Retweeted

     Jun 7

    More

    There is till time to visit us at , booth 1344. If you require nucleosides and carbohydrates for your business, come to speak to our specialist – maybe we can help.

    0 replies1 retweet1 like
    Reply
    Retweeted

    1

    Liked

    1

    Direct message
  85.   Retweeted

     Jun 7

    More

    Thank you and for helping me meet a real life superhero. Ashanti DeSilva the first person in the world treated with 28 years ago. A passionate , advocate and a personal inspiration

    0 replies4 retweets12 likes
    Reply
    Retweeted

    4

    Liked

    12

    Direct message
  86.   Retweeted

     Jun 7

    More

    .: It’s easy to lose hope when we see headline after headline announcing drug failures, but the reminds us that innovation in Alzheimer’s research is thriving.

    https://twitter.com/i/cards/tfw/v1/1004703521600569345?cardname=summary_large_image&autoplay_disabled=true&forward=true&earned=true&edge=true&lang=en&card_height=344&scribe_context=%7B%22client%22%3A%22web%22%2C%22page%22%3A%22me%22%2C%22section%22%3A%22profile%22%2C%22component%22%3A%22tweet%22%7D&bearer_token=AAAAAAAAAAAAAAAAAAAAAPYXBAAAAAAACLXUNDekMxqa8h%252F40K4moUkGsoc%253DTYfbDKbT3jJPCEVnMYqilB28NHfOPqkca3qaAxGfsyKCs0wRbw#xdm_e=https%3A%2F%2Ftwitter.com&xdm_c=default5895&xdm_p=1
    0 replies2 retweets2 likes
    Reply
    Retweeted

    2

    Liked

    2

    Direct message
  87.   Retweeted

     Jun 6

    More

    Wonderful to meet Baroness Fairhead CBE, Minister of State at DIT on the UK Pavilion at

    , ,  and 6 others
    0 replies4 retweets12 likes
    Reply
    Retweeted

    4

    Liked

    12

    Direct message
  88.   Retweeted

     Jun 7

    More

    The expo floor is a trip around the world of innovation!

    0 replies11 retweets34 likes
    Reply
    Retweeted

    11

    Liked

    34

    Direct message
  89.   Retweeted

     Jun 6

    More

    Great reception at Startup Stadium today. It’s been a great week here in Boston.

    0 replies2 retweets10 likes
    Reply
    Retweeted

    2

    Liked

    10

    Direct message
  90.   Retweeted

     Jun 7

    More

    No rest for attendees! It’s the last day of Convention, but the action isn’t slowing down yet. Look out for these featured events in today’s schedule:

    0 replies5 retweets7 likes
    Reply
    Retweeted

    5

    Liked

    7

    Direct message
  91.   Retweeted

     Jun 7

    More

    It was another history-making ! We look forward to hosting you in on 2019 to make even more history!

    0 replies5 retweets8 likes
    Reply
    Retweeted

    5

    Liked

    8

    Direct message
  92.   Retweeted

     Jun 7

    More

    Pitt has once again surpassed its records for startups in fiscal 2019 with 21 companies spun out of the university. Could a Pitt startup be your next entrepreneurial or investment opportunity?

    0 replies6 retweets12 likes
    Reply
    Retweeted

    6

    Liked

    12

    Direct message
  93.   Retweeted

     Jun 6

    More

    I will survive! ⁦⁩ very Darwinian!

    0 replies2 retweets7 likes
    Reply
    Retweeted

    2

    Liked

    7

    Direct message
  94.   Retweeted

     Jun 7

    More
    Replying to 

    No “jail” means being forced to listen to speak at . I hope he’s wearing cool socks.

    2 replies1 retweet10 likes
    Reply

    2

    Retweeted

    1

    Liked

    10

    Direct message
  95.   Retweeted

     Jun 6

    More

    Don Seiffert Retweeted Suzanne Fraser

    Diana Ross performing “I Will Survive” at the Convention Center for

    Don Seiffert added,

    0:20
    This woman is amazing….actually FABULOUS is a better word. 💃🏾🎶
    0 replies2 retweets15 likes
    Reply
    Retweeted

    2

    Liked

    15

    Direct message
  96.   Retweeted

     Jun 7

    More

    Agendia Retweeted PMC

    Thanks for inviting our CMO, Dr William Audeh, to join this important and timely in Action panel at

    Agendia added,

    “ & Dx Track” has showed progress on several policy fronts. But , , reps say providers are still not incentivized to deliver holistic, value-based…
    1 reply4 retweets9 likes
    Reply

    1

    Retweeted

    4

    Liked

    9

    Direct message
  97.   Retweeted

     Jun 7

    More

    Last day for and last chance to meet 10 companies from and health cluster. Visit us on booth 527, France pavilion.

    , ,  and 6 others
    0 replies11 retweets11 likes
    Reply
    Retweeted

    11

    Liked

    11

    Direct message
  98.   Retweeted

     Jun 7

    More

    Still time to visit us at booth 1753

    , ,  and 3 others
    0 replies5 retweets8 likes
    Reply
    Retweeted

    5

    Liked

    8

    Direct message
  99.   Retweeted

     Jun 7

    More

    Find and meet our BD Manager Emmanuelle Astoul who is attending in Boston to talk about collaboration opportunities with

    0 replies1 retweet2 likes
    Reply
    Retweeted

    1

    Liked

    2

    Direct message
  100.   Retweeted

     Jun 7

    More

    Today last day! Come visit us at booth #1328 and enjoy some argentinian alfajores and coffee!

    0 replies1 retweet2 likes
    Reply
    Retweeted

    1

    Liked

    2

    Direct message
  101.   Retweeted

     Jun 7

    More

    Today at 10:30am, join our Senior Investment Director, Dr. Karen Hong at for “Business Development & Finance: An Investor’s Perspective on Value of New Biotherapeutics” in Room 252AB, Level 2.

    0 replies1 retweet9 likes
    Reply
    Retweeted

    1

    Liked

    9

    Direct message
  102.   Retweeted

     Jun 7

    More

    Fun session y’day at on drug prices, R&D cost, and innovation – many thanks to & ! Good convo abt whether (a) competition will ⬇️ prices in cancer and rare dz, & (b) NIH, prizes, etc. can sustain & focus Rx innovation in the future.

    0 replies2 retweets7 likes
    Reply
    Retweeted

    2

    Liked

    7

    Direct message
  103.   Retweeted

     Jun 7

    More

    Speak to our Team on the UK Pavilion (stand 1333) at the Bio International Convention

    0 replies2 retweets1 like
    Reply
    Retweeted

    2

    Liked

    1

    Direct message
  104.   Retweeted

     Jun 7

    More

    Want to learn more about collaboration between and JPEO-CBRND? Stop by booth 1913 to learn more and how Industry can engage with us.

    0 replies1 retweet1 like
    Reply
    Retweeted

    1

    Liked

    1

    Direct message
  105.   Retweeted

     Jun 7

    More

    Home stretch! Day 4 begins with business development first thing in the morning. .

    0 replies4 retweets12 likes
    Reply
    Retweeted

    4

    Liked

    12

    Direct message
  106.   Retweeted

     Jun 7

    More

    Last day of kicks off with fireside chat in one hour

    0 replies1 retweet3 likes
    Reply
    Retweeted

    1

    Liked

    3

    Direct message
  107.   Retweeted

     Jun 7

    More

    My big takeaway from covering Hong Kong’s quest to build a public biotech market: Everything’s happening crazy fast. Consider yday’s news: -Hua Med applies to list – breaks news on Grail’s listing plans -HK delegation goes on a roadshow at

    https://twitter.com/i/cards/tfw/v1/1004698600570531840?cardname=summary_large_image&autoplay_disabled=true&forward=true&earned=true&edge=true&lang=en&card_height=344&scribe_context=%7B%22client%22%3A%22web%22%2C%22page%22%3A%22me%22%2C%22section%22%3A%22profile%22%2C%22component%22%3A%22tweet%22%7D&bearer_token=AAAAAAAAAAAAAAAAAAAAAPYXBAAAAAAACLXUNDekMxqa8h%252F40K4moUkGsoc%253DTYfbDKbT3jJPCEVnMYqilB28NHfOPqkca3qaAxGfsyKCs0wRbw#xdm_e=https%3A%2F%2Ftwitter.com&xdm_c=default5896&xdm_p=1
    1 reply7 retweets5 likes
    Reply

    1

    Retweeted

    7

    Liked

    5

    Direct message
  108.   Retweeted

     Jun 7

    More

    At Shares the Journey: being an award-winning broadcast journalist and author, and a survivor of breast cancer and myelodysplastic syndrome (MDS),

    0 replies3 retweets9 likes
    Reply
    Retweeted

    3

    Liked

    9

    Direct message
  109.   Retweeted

     Jun 7

    More

    Over the past 21 years, we’ve forged long-term, mutually successful partnerships, bringing innovations and solutions together to meet the worlds healthcare needs. Connect with us at the Scottish Pavillion to discover what we can do for your clinical trial journey.

    0 replies1 retweet4 likes
    Reply
    Retweeted

    1

    Liked

    4

    Direct message
  110.   Retweeted

     Jun 7

    More

    ⁦⁩ hosted a great alumni networking event around

    0 replies1 retweet4 likes
    Reply
    Retweeted

    1

    Liked

    4

    Direct message

  111.  Jun 7

    More

    Thomas Jefferson University announces Global Center in Israel best choice -tech

    https://twitter.com/i/cards/tfw/v1/1004704365599449094?cardname=summary_large_image&autoplay_disabled=true&forward=true&earned=true&edge=true&lang=en&card_height=344&scribe_context=%7B%22client%22%3A%22web%22%2C%22page%22%3A%22me%22%2C%22section%22%3A%22profile%22%2C%22component%22%3A%22tweet%22%7D&bearer_token=AAAAAAAAAAAAAAAAAAAAAPYXBAAAAAAACLXUNDekMxqa8h%252F40K4moUkGsoc%253DTYfbDKbT3jJPCEVnMYqilB28NHfOPqkca3qaAxGfsyKCs0wRbw#xdm_e=https%3A%2F%2Ftwitter.com&xdm_c=default5897&xdm_p=1
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity
  112.   Retweeted

     Jun 6

    More

    Rob Reiner and I will be joining you on stage shortly!

    0 replies8 retweets30 likes
    Reply
    Retweeted

    8

    Liked

    30

    Direct message
  113.   Retweeted

     Jun 5

    More

    Are you at ? Be sure to stop by Booth #2101 to learn more about the 10 remarkable Israeli companies, spanning the spectrum of ’s vigorous Life Sciences community- from innovative start-ups to established companies!

    , ,  and 5 others
    3 replies17 retweets42 likes
    Reply

    3

    Retweeted

    17

    Liked

    42

    Direct message
  114.   Retweeted

     Jun 6

    More

    Great discussion at today’s “Best Practices for Working with Patient Advocacy Organizations,” with our own Jessica Riviere, Senior Director, Biogen

    0 replies7 retweets20 likes
    Reply
    Retweeted

    7

    Liked

    20

    Direct message
  115.   Retweeted

     Jun 6

    More

    We are excited to have , CEO of with us live at the Massachusetts pavilion speaking live

    ,  and 
    0 replies6 retweets19 likes
    Reply
    Retweeted

    6

    Liked

    19

    Direct message
  116.   Retweeted

     Jun 6

    More

    Our President of R&D Akshay Vaishnaw took the stage earlier today at the pavilion to tell our innovation and Massachusetts story. therapeutics

    0 replies8 retweets17 likes
    Reply
    Retweeted

    8

    Liked

    17

    Direct message
  117.   Retweeted

     Jun 5

    More

    Standing ovation for Ashanthi De Silva at ! “Have hope, be your own advocate, and never give up.” – at Boston Convention Center Grand Ballroom

     and 
    0 replies7 retweets18 likes
    Reply
    Retweeted

    7

    Liked

    18

    Direct message
  118.   Retweeted

     Jun 6

    More

    Diversity and inclusion is an BoD priority, an priority and my priority. During my fireside chat w/ Halozyme CEO Helen Torley today at , I committed to not participate in any future panel that is not diverse.

    4 replies15 retweets84 likes
    Reply

    4

    Retweeted

    15

    Liked

    84

    Direct message
  119.   Retweeted

     Jun 5

    More

    Here in Massachusetts, innovation is a way of life. It truly is the . If you want it to happen, you need to be here – Massachusetts is the place where life sciences companies can find the people, the ideas and the resources they need to innovate and grow. – at Boston Convention & Exhibition Center

    , ,  and 
    6 replies52 retweets133 likes
    Reply

    6

    Retweeted

    52

    Liked

    133

    Direct message
  120.   Retweeted

     Jun 6

    More

    We OFFICIALLY made history this week! BIO’s Joanne Duncan accepting our Guinness World Record for ‘Largest Business Parneting Event’

    3 replies25 retweets72 likes
    Reply

    3

    Retweeted

    25

    Liked

    72

    Direct message
  121.   Retweeted

     Jun 6

    More

    Excited to hear member and Reg Affairs Committee member Kelli Tanzella of give her perspective on the regulatory paradigm for NGS panels.

    1 reply4 retweets8 likes
    Reply

    1

    Retweeted

    4

    Liked

    8

    Direct message
    Show this thread
  122.   Retweeted

     Jun 6

    More

    Trailblazing discoveries in health sciences are what we do here.

    0 replies7 retweets8 likes
    Reply
    Retweeted

    7

    Liked

    8

    Direct message
  123.   Retweeted

     Jun 6

    More

    Did you know that every 3.5 minutes someone will die from lung cancer? Boston University and investing in changing this

    0 replies9 retweets6 likes
    Reply
    Retweeted

    9

    Liked

    6

    Direct message
  124.   Retweeted

     Jun 6

    More

    We did it! We set a world record for the Largest Business Partnering Event. Thank you to everyone!

    0 replies6 retweets20 likes
    Reply
    Retweeted

    6

    Liked

    20

    Direct message
  125.   Retweeted

     Jun 6

    More

    I’ve been around the world twice. is the Epcot of Bio, Science & Pharma companies. Proud to see companies recognizing the Making great connections to support our students.

    0 replies5 retweets9 likes
    Reply
    Retweeted

    5

    Liked

    9

    Direct message
  126.   Retweeted

     Jun 6

    More

    Eager to elevate the & voice at this morning’s panel discussion on Communicating Value Through the Eye of the Beholder

    , ,  and 5 others
    2 replies14 retweets49 likes
    Reply

    2

    Retweeted

    14

    Liked

    49

    Direct message
  127.   Retweeted

     Jun 6

    More

    Need for evidence of PM’s value has emerged as “ & Dx Track” theme. Now, , , reps show / parallel review pathway, joint studies by commercial insurers/Dx companies will be key.

    0 replies1 retweet5 likes
    Reply
    Retweeted

    1

    Liked

    5

    Direct message
  128.   Retweeted

     Jun 6

    More

    The winner of Dr. Paul Janssen Award Jim Allison discusses the importance of elevating science to a household conversation if we want to improve our collective health.

    , ,  and 5 others
    0 replies6 retweets9 likes
    Reply
    Retweeted

    6

    Liked

    9

    Direct message
  129.   Retweeted

     Jun 6

    More

    Congrats to for setting the Guinness World Record for largest business partnering event!

    0 replies8 retweets26 likes
    Reply
    Retweeted

    8

    Liked

    26

    Direct message
  130.   Retweeted

     Jun 6

    More

    Diversity and inclusion in science goes beyond who’s at the bench and all the way to who the science serves – 80% of NIH’s genomic data that’s used to push forward precision medicine is from people of European descent. (That’s not okay)

    2 replies10 retweets17 likes
    Reply

    2

    Retweeted

    10

    Liked

    17

    Direct message
  131.   Retweeted

     Jun 6

    More

    speed networking is happening now! Booth #2001

    0 replies4 retweets4 likes
    Reply
    Retweeted

    4

    Liked

    4

    Direct message
  132.   Retweeted

     Jun 6

    More

    Honored to have had the opportunity to address this morning and talk about how real, palpable ultimately means real, palpable patient impact!

    0 replies13 retweets45 likes
    Reply
    Retweeted

    13

    Liked

    45

    Direct message
  133.   Retweeted

     Jun 6

    More

    We don’t do germline editing; society is not at a place to be ready for this, also it’s against recs, says Sandy Macrae . Carrie Wolinetz agrees, says term distinction is crucial, confusing these can feed back into regulatory framework detrimentally.

    0 replies3 retweets5 likes
    Reply
    Retweeted

    3

    Liked

    5

    Direct message
  134.   Retweeted

     Jun 6

    More

    What question would you ask at a discussion about the regulatory framework in human genome editing?

    0 replies2 retweets3 likes
    Reply
    Retweeted

    2

    Liked

    3

    Direct message
  135.   Retweeted

     Jun 6

    More

    “One patient at a time, positive responses are demonstrating that RNAi technology indeed has the potential to bring about a paradigm shift in medicine,” writes Mano Manoharan, SVP, Innovation Chemistry, in a blog post discussing our journey to advance therapeutics.

    https://twitter.com/i/cards/tfw/v1/1004422669507297280?cardname=promo_website&autoplay_disabled=true&forward=true&earned=true&edge=true&lang=en&card_height=271&scribe_context=%7B%22client%22%3A%22web%22%2C%22page%22%3A%22me%22%2C%22section%22%3A%22profile%22%2C%22component%22%3A%22tweet%22%7D&bearer_token=AAAAAAAAAAAAAAAAAAAAAPYXBAAAAAAACLXUNDekMxqa8h%252F40K4moUkGsoc%253DTYfbDKbT3jJPCEVnMYqilB28NHfOPqkca3qaAxGfsyKCs0wRbw#xdm_e=https%3A%2F%2Ftwitter.com&xdm_c=default5898&xdm_p=1
    0 replies3 retweets6 likes
    Reply
    Retweeted

    3

    Liked

    6

    Direct message
  136.   Retweeted

     Jun 6

    More

    The opportunities to advance the clinical trial model with personalized and targeted approaches are endless, from in the

    0 replies7 retweets11 likes
    Reply
    Retweeted

    7

    Liked

    11

    Direct message
  137.   Retweeted

     Jun 6

    More

    Fantastic dialogue going on in 204AB at . Completely candid remarks from tremendous group

    0 replies2 retweets1 like
    Reply
    Retweeted

    2

    Liked

    1

    Direct message
  138.   Retweeted

     Jun 6

    More

    It was great to meet Jim Greenwood, CEO of at . – Robert Naismith, Chairman

    0 replies2 retweets7 likes
    Reply
    Retweeted

    2

    Liked

    7

    Direct message
  139.   Retweeted

     Jun 6

    More

    Wow knows how to put a stellar diverse panel together 🙌

    , ,  and 6 others
    0 replies3 retweets16 likes
    Reply
    Retweeted

    3

    Liked

    16

    Direct message
  140.   Retweeted

     Jun 6

    More

    Front and center, Maryland is in a prime position to move business and innovation forward!

    0 replies5 retweets14 likes
    Reply
    Retweeted

    5

    Liked

    14

    Direct message
  141.   Retweeted

     Jun 6

    More

    This is a loaded panel & plenty of seats avail. Turbo charge R&D activities in 252AB

    0 replies1 retweet4 likes
    Reply
    Retweeted

    1

    Liked

    4

    Direct message
  142.   Retweeted

     Jun 6

    More

    Q to panel as public co CEOs – how do you investor risk? Dahiyat says people will invest if they think co. will make money either way. Hastings says will push some away, draw others in, so do what’s right.

    0 replies1 retweet2 likes
    Reply
    Retweeted

    1

    Liked

    2

    Direct message
  143.   Retweeted

     Jun 6

    More

    Our Biocom team has been taking full advantage of making ALL the connections at ! Check us out at the California Pavilion or stop by Startup Stadium tomorrow where we’ll be supporting our member !

    , ,  and 
    0 replies5 retweets15 likes
    Reply
    Retweeted

    5

    Liked

    15

    Direct message
  144.   Retweeted

     Jun 6

    More

    For those interested in learning more about gene-based therapies, make sure to attend the “Making Genetic Therapies a Reality for Patients” panel featuring our Chief Commercial Officer, Emmanuel Dulac.

    0 replies1 retweet6 likes
    Reply
    Retweeted

    1

    Liked

    6

    Direct message
  145.   Retweeted

     Jun 6

    More

    “ & Dx Track” has showed progress on several policy fronts. But , , reps say providers are still not incentivized to deliver holistic, value-based medicine. Reimbursement paradigms must evolve, they say.

    0 replies1 retweet4 likes
    Reply
    Retweeted

    1

    Liked

    4

    Direct message
  146.   Retweeted

     Jun 6

    More

    Travis McCready from closes out the Possible Talks at in the – “The only way that this industry will evolve, the only way we’ll find cures, is to develop the next generation of diverse talent and to break the mold.” That’s a wrap!

    0 replies17 retweets39 likes
    Reply
    Retweeted

    17

    Liked

    39

    Direct message
  147.   Retweeted

     Jun 6

    More

    “Breakthrough cience occurs when you cross disciplines” Mikael Dolsten

    0 replies1 retweet2 likes
    Reply
    Retweeted

    1

    Liked

    2

    Direct message
  148.   Retweeted

     Jun 6

    More

    🛑! Working on a slide deck to communicate your awesome 🔬? Here are some presentation basic design tips 🎨 for this week’s !

    1 reply2 retweets12 likes
    Reply

    1

    Retweeted

    2

    Liked

    12

    Direct message
    Show this thread
  149.   Retweeted

     Jun 6

    More

    Representatives from European biotech, regulatory and venture capital describe the state of investments in Europe and how global participants can get involved

    0 replies1 retweet1 like
    Reply
    Retweeted

    1

    Liked

    1

    Direct message
  150.   Retweeted

     Jun 6

    More

    Great to meet Australia’s top medical entrepreneurs, discussing how they can take their successful ideas global, creating more jobs and improving patient outcomes

    6 replies6 retweets42 likes
    Reply

    6

    Retweeted

    6

    Liked

    42

    Direct message
  151.   Retweeted

     Jun 6

    More

    Biologos is having a great time at this week in Boston!

    0 replies1 retweet3 likes
    Reply
    Retweeted

    1

    Liked

    3

    Direct message
  152.   Retweeted

     Jun 6

    More

    Great panel at on Digiral Medicines with leaders of of of Marisa Cruz of and Mostafa Kamal of Magellan

    0 replies4 retweets16 likes
    Reply
    Retweeted

    4

    Liked

    16

    Direct message
  153.   Retweeted

     Jun 6

    More

    Great points from re patient consent, consent for life, by Sandy Macrae, and need to ensure patients truly understand what it is they are committing to

    0 replies3 retweets4 likes
    Reply
    Retweeted

    3

    Liked

    4

    Direct message
  154.   Retweeted

     Jun 6

    More

    Q based on diversity training: anybody willing to do training similar to Starbucks? Dahiyat says his company already diverse, but reaches out to area to encourage diversity in science. Johnson says similar program at Dare – get more diversity in science with local youth.

    0 replies1 retweet2 likes
    Reply
    Retweeted

    1

    Liked

    2

    Direct message
  155.   Retweeted

     Jun 6

    More

    Over a 7-year period biotech job growth outpaced national growth by 14% Visit to find out why call home

    0 replies4 retweets5 likes
    Reply
    Retweeted

    4

    Liked

    5

    Direct message
  156.   Retweeted

     Jun 6

    More

    Life sciences companies aren’t innovating processes with and other technologies, but whoever tackles this first will win. from leads a discussion at with leaders from , , , and .

    0 replies3 retweets6 likes
    Reply
    Retweeted

    3

    Liked

    6

    Direct message
  157.   Retweeted

     Jun 6

    More

    🇦🇷 esta presente en la 2018! . . .

    0 replies1 retweet8 likes
    Reply
    Retweeted

    1

    Liked

    8

    Direct message
  158.   Retweeted

     Jun 6

    More

    Independent test results confirm the new VIP ECO upright ultra-low temperature freezer has the lowest total daily energy usage in its class in the industry. Visit us at this week Booth 1927 to learn more. Download your white paper here:

    0 replies2 retweets4 likes
    Reply
    Retweeted

    2

    Liked

    4

    Direct message
  159.   Retweeted

     Jun 6

    More

    DrugDeliveryExperts Retweeted BIO Intl Convention

    And DDE was there… Congrats to !

    DrugDeliveryExperts added,

    We MADE GUINNESS HISTORY!
    0 replies1 retweet2 likes
    Reply
    Retweeted

    1

    Liked

    2

    Direct message
  160.   Retweeted

     Jun 6

    More

    Save the date… reminding everyone at to come visit us next year in !

    0 replies3 retweets8 likes
    Reply
    Retweeted

    3

    Liked

    8

    Direct message
  161.   Retweeted

     Jun 6

    More

    Some impressions representing trends on : , driving the funnel and from all over the world – at Boston Convention & Exhibition Center

    , ,  and 
    0 replies3 retweets12 likes
    Reply
    Retweeted

    3

    Liked

    12

    Direct message
  162.   Retweeted

     Jun 6

    More

    “Europe is a uniquely attractive place for biotech”; lively discussion at our session on Europe’s value proposition for + investment

    0 replies3 retweets6 likes
    Reply
    Retweeted

    3

    Liked

    6

    Direct message
  163.   Retweeted

     Jun 6

    More

    Dahiyat continues: If you are running your business in a way that is profitable, investors won’t care. If not, it doesn’t matter if you’re silent anyway.

    0 replies1 retweet2 likes
    Reply
    Retweeted

    1

    Liked

    2

    Direct message
    Show this thread
  164.   Retweeted

     Jun 6

    More

    Thank you for joining today’s panel with and the and for working with us to bring the patient viewpoint forward in value assessment.

    0 replies2 retweets3 likes
    Reply
    Retweeted

    2

    Liked

    3

    Direct message
  165.   Retweeted

     Jun 6

    More

    Now on stage at former MA governor ; extremely inspiring and a good example that a strong political vision is a key to Life Sciences Cluster development

    0 replies3 retweets10 likes
    Reply
    Retweeted

    3

    Liked

    10

    Direct message
  166.   Retweeted

     Jun 6

    More

    Hats off to — Been coming for most of the last 15 years, and I’ve never seen this level of buzz about business, doing things, in . Congrats on a job well done.

    0 replies9 retweets50 likes
    Reply
    Retweeted

    9

    Liked

    50

    Direct message
  167.   Retweeted

     Jun 6

    More

    Today Paul Stoffels, CSO of will be discussing new strategies for the development of & for the developing world. If you’re at head to Room 251, Level 2 at 3:00pm.

    0 replies6 retweets10 likes
    Reply
    Retweeted

    6

    Liked

    10

    Direct message
  168.   Retweeted

     Jun 6

    More

    Fireside Chat speaker and BIO Board of Directors chair on diversity and business

    0 replies1 retweet5 likes
    Reply
    Retweeted

    1

    Liked

    5

    Direct message
  169.   Retweeted

     Jun 6

    More

    THE is performing LIVE at TONIGHT at the BCEC! You must have a Convention Access badge to enter, and warning: space is extremely limited. Admittance is first-come, first-served, so make sure to arrive early! Thanks to our sponsors

    0 replies3 retweets15 likes
    Reply
    Retweeted

    3

    Liked

    15

    Direct message
  170.   Retweeted

     Jun 5

    More

    WIB Pittsburgh Retweeted Women In Bio

    For those of you at , check this out!

    WIB Pittsburgh added,

    We’re here at Booth #2501! Stop by and chat! Don’t miss out our other events during :
    1 reply5 retweets22 likes
    Reply

    1

    Retweeted

    5

    Liked

    22

    Direct message
  171.   Retweeted

     Jun 2

    More

    Mark your calendars! Chief Scientific Officer Paul Stoffels will sit down with founder on Monday at 4pm at to discuss how we can speed innovation in science and medicine.

    0 replies23 retweets45 likes
    Reply
    Retweeted

    23

    Liked

    45

    Direct message
  172.   Retweeted

     Jun 5

    More

    I believe in dreaming big and focusing small ~ great words to live by. BIOConvention

    ,  and 
    1 reply12 retweets53 likes
    Reply

    1

    Retweeted

    12

    Liked

    53

    Direct message
  173.   Retweeted

     Jun 4

    More

    So much going on today at ! Keynotes from industry leaders, panels on cutting edge research, and 1×1 partnering now happening in the Business Forum!

    0 replies11 retweets33 likes
    Reply
    Retweeted

    11

    Liked

    33

    Direct message
  174.   Retweeted

     Jun 4

    More

    To all who will be attending this week, a very warm welcome to my adopted hometown…AKA “The City of Champions” (in case you’ve forgotten!).

    9 replies19 retweets142 likes
    Reply

    9

    Retweeted

    19

    Liked

    142

    Direct message
  175.   Retweeted

     Jun 2

    More

    It’s no wonder is in Massachusetts next week. Great things are happening here for the economy and for patients.

    https://twitter.com/i/cards/tfw/v1/1002915122543816704?cardname=summary_large_image&autoplay_disabled=true&forward=true&earned=true&edge=true&lang=en&card_height=344&scribe_context=%7B%22client%22%3A%22web%22%2C%22page%22%3A%22me%22%2C%22section%22%3A%22profile%22%2C%22component%22%3A%22tweet%22%7D&bearer_token=AAAAAAAAAAAAAAAAAAAAAPYXBAAAAAAACLXUNDekMxqa8h%252F40K4moUkGsoc%253DTYfbDKbT3jJPCEVnMYqilB28NHfOPqkca3qaAxGfsyKCs0wRbw#xdm_e=https%3A%2F%2Ftwitter.com&xdm_c=default5899&xdm_p=1
    2 replies36 retweets85 likes
    Reply

    2

    Retweeted

    36

    Liked

    85

    Direct message
  176.   Retweeted

     Jun 5

    More

    As an industry, we will continue to champion the evolution of “patients as subjects” to “patients as partners.” They’re the real experts in their conditions. They’re following the research. They’re clinical pioneers. And they’re our real-life inspirations.

    5 replies31 retweets71 likes
    Reply

    5

    Retweeted

    31

    Liked

    71

    Direct message
  177.   Retweeted

     Jun 4

    More

    Enjoyed dinner w/ cool and fun power women Cat Oyler, Suzy Lebold Sue Dillon, Reema Driscoll

    2 replies7 retweets63 likes
    Reply

    2

    Retweeted

    7

    Liked

    63

    Direct message

Read Full Post »

News Release BIO 2018 Makes History in Boston – Attendees, Sessions and Videos highlights

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital on June 8, 2018| Leave a Comment »

News Release BIO 2018 Makes History in Boston – Attendees, Sessions and Videos highlights

Reporter: Aviva Lev-Ari, PhD, RN

News Release

 

 

 

1201 Maryland Avenue, SW l Ste. 900 l Washington, D.C. l 20024 l 202-962-9200

 

Web:www.bio.org           Blog:www.biotech-now.org           Twitter: @IAmBiotech

 

 

 

For Immediate Release

Contact:

Theresa Brady

202.997.9034

BIO 2018 Makes History in Boston 

 

In celebration of its 25th anniversary, BIO recognizes progress made

and the transformative innovations yet to come

 

Boston, MA – (June 7, 2018) – The 2018 BIO International Convention (BIO 2018) today wrapped up four days of programming under the theme of “Make History.” Hosted by the Biotechnology Innovation Organization (BIO), BIO 2018 attracted thousands of U.S. and international attendees, celebrated innovations that have shaped the past 25 years and recognized the companies, patient groups, academic centers and investors that continue to advance novel solutions to the world’s toughest challenges.

The Convention drew 18,289 biotechnology industry leaders – the most attendees in the last 10 years – from 49 states, the District of Columbia, Puerto Rico and 67 countries.

 

“This year’s 2018 BIO Convention demonstrated, more than ever, that partnering and collaboration will drive cutting-edge advancements and propel the industry forward,” said Joanne Duncan, President, Membership and Business Operations at BIO. “With 46,916 one-on-one meetings held during the last four days, we know that the knowledge exchange and partnerships forged this week have the potential to transform our world for the better.”

To encourage students to attend BIO and learn more about careers in the biotechnology industry, BIO 2018 included the first Free Student Day. Eligible participants got a one-day Exhibition Access registration and the opportunity to meet with representatives from the biotechnology community. The breadth and depth of offerings and the networking opportunities afforded to thousands of industry stakeholders and students continues to make the Convention the premiere event for the biotechnology industry.

 

BIO 2018 drew companies, academic centers, patient groups, researchers and investors working to advance innovation in key areas such as drug development, brain health, digital health, oncology, opioids, renewable fuels and agriculture. Celebrities also made a presence at BIO, with stories of triumphs over illnesses such as cancer and addiction. Robin Roberts, a cancer survivor and an award-winning journalist, and Rob Reiner, an actor, director and advocate, delivered keynote addresses that emphasized the challenges faced by patients, the importance of patient advocacy and the need for continued innovation to address unmet needs.

 

This year’s International Convention was held with the support of BIO’s state affiliate organization MassBio.

 

“MassBio and our members were thrilled to welcome the world to Massachusetts this week, so they can see firsthand why we’re the state of possible,” said Robert K. Coughlin, President and CEO of MassBio. “From Cambridge to Worcester to Springfield, our state is the hub of biotechnology innovation, and BIO 2018 allowed us to show what’s possible when industry, academia, and government work together as partners to advance patient health worldwide.”

Setting a Guinness World Record for “The Largest Business Partnering Event,” BIO 2018 hosted 46,916 partnering meetings, facilitated by BIO’s One-on-One Partnering™ system— a 13% increase over 2017. These invaluable connections form the foundation of innovative industry collaborations and scientific breakthroughs.

BIO 2018 also included over 1,800 exhibitors, more than a thousand speakers, 180 sessions, 17 plus super sessions and fireside chats and 19 education tracks. Special programming, such as the Start-Up Stadium, also provided a forum for up and coming companies to receive invaluable advice to accelerate their growth and potential.

 

Videos highlights of BIO 2018 can be found here.

The 2019 BIO International Convention will take place in Philadelphia from June 3-6. In 2020, the Convention returns to San Diego for the fourth time from June 8-11.

 

About BIO

BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO’s blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

 

###

 

Contacts

Biotechnology Innovation Organization (BIO)

Theresa Brady

202-997.9034

Web: www.bio.org

Blog: www.biotech-now.org

Twitter: @IAmBiotech

SOURCE

From: Colleen Connolly <cconnolly@we-worldwide.com>

Date: Thursday, June 7, 2018 at 5:22 PM

To: Colleen Connolly <cconnolly@we-worldwide.com>

Subject: Press Release: BIO 2018 Makes History in Boston

Read Full Post »

Biotechnology Financing, Deal-Making and State of the Industry: Findings from EY Industry Analysis, June 5, 1:45-2:45PM, BIO 2018!, Boston, BCEC

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media on June 5, 2018| Leave a Comment »

Biotechnology Financing, Deal-Making and State of the Industry: Findings from EY Industry Analysis, June 5, 1:45-2:45PM, BIO 2018!, Boston, BCEC

Reporter: Aviva Lev-Ari, PhD, RN

 

1:45 PM–2:45 PMJun 5, 2018

business_icon

Business Development & Finance

Biotechnology Financing, Deal-Making and State of the Industry: Findings from EY Industry Analysis
Speakers
  • Valuation for 23andme?
  • Each pool of capital has different investors been attracted
  • Science is extraordinary
  • A lot of capital and very many tech ventures
  • over supply of capital accelerates the business
  • More capital is better, understanding in what to invest is critical
  • 2015 greatest year of capital availability
  • Venture (private) capital (US and Europe)
  • Life Sciences M&A – New players and abundant Capital
  • Partnering with investors is critical rounds be bigger and faster
  • In 16 years rained $4Billion and expenses $2.5Billion
  • Orphan Drug for rare disease: Genzyme sold for $18Billion – MS drug
  • Immuno-Oncology: Juno and Kite ~$13Billion
  • New Theory  – came at late stage private company, invest again after iPO then gone
  • Investor’s decision if to invest in early stage or come late??
LOCATION

Room 257AB, Level 2

Read Full Post »

Tales from the Translational Frontier – Four Unique Approaches to Turning Novel Biology into Investable Innovations @BIOConvention #BIO2018

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media, Foundations for supporting Science and Education, Translational Science on June 4, 2018| Leave a Comment »

Tales from the Translational Frontier – Four Unique Approaches to Turning Novel Biology into Investable Innovations @BIOConvention #BIO2018

Reporter: Aviva Lev-Ari, PhD, RN

translationalresearch
Tales from the Translational Frontier – Four Unique Approaches to Turning Novel Biology into Investable Innovations

Translational Research

 2:30 PM–3:45 PM Jun 4, 2018

 Room 206AB, Level 2

Moderator (1)

357755

Speaker (4)

357758

357757

357756

SEE ALL

Who’s Attending (202)

bio2018-mybio-icons-attendees

412311

357940

356138

download

SMS-Oncology_HiRes_C7A7908

0

Esmeralda Megally photo

IMG_3535

DSC_9695

brad

userPhoto

Description

The translational pipeline of medical innovation that flows from academic research centers is at the heart of modern society’s ability to turn the explosion of biological discovery into transformative new medicines. A variety of different models have emerged to overcome the inherent challenges in identifying and advancing biological discoveries to a point where they become investable and can attract private sector partners capable of completing their development, regulatory approval and commercialization. However, most of these models involve academic medical centers, pharma companies and venture investors in the established biotech hubs.
This panel will explore how four distinctive programs that lie outside the flourishing ecosystems of the major biotech centers have been navigating the translational landscape and turning inventions into investable innovations.

Ability Level: All

Session ID: 21200

Tags
Interest AreaTranslational Research
Session TracksTranslational Research
Session TypesBreakout Sessions
Session TypesAll
Session TypesInteractive Panel
Session TypesInteractive Panel

Read Full Post »

BIO 2018! June 4-7, 2018 at Boston Convention & Exhibition Center

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media on May 26, 2018| Leave a Comment »

BIO 2018! June 4-7, 2018 at Boston Convention & Exhibition Center

Announcement

Aviva Lev-Ari, PhD, RN,

https://mybio.org/

https://mybio.org/profile/member/2029564?profile_tabs=profile

Founder and Director of LPBI Group will be in attendance covering the event in REAL TIME

@pharma_BI

@AVIVA1950

 

All TWEETS from LPBI’s Twitter.com handles at

@pharma_BI

@AVIVA1950

for

#BIO2018

@BIOConvention

 

Program Overview

#BIO2018

@BIOConvention

@pharma_BI

@AVIVA1950

  • FIRE CHATS

 

BIO’s top-notch education program covers the biotechnology and pharma industry’s most relevant and timely topics – providing the know-how you need to advance your business. In each session, top thought leaders offer insights on issues essential to the industry and provide a wealth of information of strategic relevance to your business. We have hundreds of sessions to choose from!

On Tuesday June 5, U.S. Health and Human Services Assistant Secretary for Preparedness and Response, Dr. Robert Kadlec, and Deputy Assistant Secretary, Dr. Rick Bright, will announce a new initiative authorized by the 21st Century Cures Act, passed in December 2016.

The new initiative will accelerate cutting-edge health technology aimed at health security challenges like early detection of illness and sepsis. With the potential to affect major healthcare markets, the new program will bring together innovative ideas from across the country, the proven track record of BARDA, and best practices from DARPA and venture capital, to shape the next generation of lifesaving technology. 

 

Who:                                        Robert Kadlec, M.D., HHS Assistant Secretary for Preparedness and Response

Rick Bright, Ph.D., Director, Biomedical Advanced Research and Development Authority (BARDA) and Deputy Assistant Secretary for Preparedness and Response

When:                                      12:30 p.m. EDT, Tuesday, June 5, 2018

How:                                         BIO 2018 International Convention

                                                    415 Summer St, Boston, Room 153B (level 1, north lobby)

                                                    OR call 888-769-8792, passcode 5693715

Additional information:     Contact ASPRComms@hhs.gov to confirm participation during the BIO International Convention in Boston.

Personalized Medicine Session

JUNE 5, 2018

11:00 a.m. — Precision Medicine: Coming of Age

Room | 259B, Level 2

  • Introduction | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition
  • Keynote Speaker | Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Harvard Medical School; Scientific Director, Harvard-Partners Center for Genetics and Genomics; Scientific Director, Brigham and Women’s Hospital

1:45 p.m. — Partnerships Power Precision Health: Collaborative Models for Advancing Personalized Medicine

Room | 259B, Level 2

This session will offer different views on the opportunities and challenges involved in collaborative efforts to deliver on the promise of personalized medicine. Panelists will offer examples and ideas for multidisciplinary collaboration.

  • Moderator | Terry Magnuson, Ph.D., Professor of Genetics, Vice Chancellor for Research, University of North Carolina School of Medicine
    • Suzanne Belinson, Ph.D., Executive Director, Center for Clinical Effectiveness, Blue Cross Blue Shield Association
    • Stephanie Devaney, Ph.D., Deputy Director, All of Us Research Program, U.S. National Institutes of Health
    • Jill Hagenkord, M.D., F.C.A.P., Chief Medical Officer, Color Genomics

3:00 p.m. — Improving Health Through Focused Screening of Populations

Room | 259B, Level 2

The potential for better outcomes, decreased costs, and insights coming from basic and translational research are driving health systems toward precision medicine. Multi-omic technologies are accelerating the path to discovery, diagnosis and treatment, and are being deployed with large-scale clinical utility. In this session, panelists will present large-scale programs aimed at screening healthy populations for actionable genetic and biochemical risk factors.

  • Moderator | Alan Sachs, M.D., Ph.D., Chief Scientific Officer, Thermo Fisher Scientific
    • Shaun Lonergan, Vice President, Corporate Development, Metabolon
    • Brian Meyer, Ph.D., Chairman, Department of Genetics, Research Centre, King Faisal Specialist Hospital and Research Centre
    • Philip Empey, Pharm.D., Ph.D., Associate Director for Pharmacogenomics, Institute for Precision Medicine, University of Pittsburgh

6:00 p.m. — Annual PMC/Foley & Lardner Cocktail Reception

Location | Legal Crossing, 558 Washington Street, Boston, MA 02111

On the evening of June 5, 2018, PMC will again welcome many of personalized medicine’s most distinguished leaders at the Annual PMC/Foley & Lardner Cocktail Reception, which will take place at Legal Crossing. The reception will feature classic East Coast cuisine and contemporary cocktails that draw influence from the neighborhood’s colorful past.

NOTE: This reception is not a formal part of the BIO Convention program. Please RSVP using the link provided even if you are already registered for the BIO Convention.

Co-organized by

JUNE 6, 2018

11:00 a.m. — The Next Generation of Personalized Medicine: A New Regulatory Paradigm for NGS Panels

Room | 259B, Level 2

The science driving personalized medicine continues to push innovation toward better patient care, but successful innovation requires technology development incentives and appropriate policies governing regulatory oversight of novel diagnostic tests and testing platforms. This panel will provide insight into the evolving status of regulatory oversight of various types of advanced diagnostics, discuss current and evolving policy at the U.S. Food and Drug Administration (FDA) and the U.S. Centers for Medicare and Medicaid Services (CMS), and explore the potential impact that these developments will have on medical research, product development, and market access.

  • Moderator | Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition
    • Mark Fleury, Ph.D., Principal, Policy Development, Emerging Science, American Cancer Society Cancer Action Network
    • Laura Koontz, Ph.D., Personalized Medicine Staff, FDA
    • Tamara Syrek Jensen, J.D., Acting Director, Coverage and Analysis Group, CMS
    • Kelli Tanzella, Ph.D., Senior Director, Global Regulatory Affairs, Thermo Fisher Scientific

1:45 p.m. — Realizing the Potential of Clinical and Consumer Genomics

Room | 259B, Level 2

This session will feature a discussion about consumer access to inexpensive sequencing technologies from companies that claim to use genetic data for various health-related objectives, from personalized training programs to better understanding disease risk. Panelists will explore the available business models and how companies are handling issues around data management, data privacy and ownership.

  • Moderator | Vivek Mittal, Ph.D., Partner, Health Advances LLC
    • Akwasi Asabere, Ph.D., Head, Business Development and Partnerships, Helix
    • Elaine Cheung, Vice President, Business Development, MindStrong Health
    • Julie Papanek Grant, Partner, Canaan Partners

3:00 p.m. — Precision Diagnostics: Trends in Evidence Development for Medicare and Commercial Payers

Room | 259B, Level 2

This session will offer an exploration of trends in how payers evaluate evidence to support coverage for precision diagnostics, highlighting the growth of the coverage with evidence development (CED) model, in which tests are covered while additional clinical utility data are collected. The discussion will focus on Medicare’s CED policy and Palmetto’s MolDx program.

  • Moderator | Brian P. Carey, J.D., Partner, Foley Hoag LLP
    • James Almas, M.D., Medical Director, MolDx Program, Palmetto GBA
    • Tom McLain, Chief Operating Officer, Exosome Diagnostics
    • Sean Tunis, M.D., Founder, CEO, Center for Medical Technology Policy

4:15 p.m. — Personalized Medicine in Action: Examples of Clinical Implementation

Room | 259B, Level 2

This session will examine two pioneer personalized medicine programs — their strategies, experiences, and successes in achieving and demonstrating value — as examples of the clinical implementation of personalized medicine and the associated health care delivery benefits.

  • Moderator | Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition
    • William Audeh, M.D., M.S., Chief Medical Officer, Agendia
    • Thomas D. Brown, M.D., Executive Director, Swedish Cancer Institute; co-Chairman, Providence Health & Services Personalized Medicine Program
    • James Ford, M.D., Director, Clinical Cancer Genetics Program, Stanford Health Care

JUNE 7, 2018

9:00 a.m. — Is Biotechnology Drowning in Health-Related Data?

Room | 259B, Level 2

This session will feature a discussion about the potential of big data initiatives in health care. Has the value of big data been over-promised? How do we separate hype from reality? What can and is being done, and what is simply big data hubris? It seems biotechnology is drowning in its own data — how will it swim?

  • Moderator | Damian Garde, National Biotech Reporter, STAT News
    • James Bradner, M.D., President, Novartis Institutes for Biomedical Research
    • Iya Khalil, Ph.D., Chief Commercial Officer, co-Founder, GNS Healthcare
    • Eric Schadt, Ph.D., CEO, Sema4

10:30 a.m. — Bridging the Gap: Adding Dynamics to the Diagnostic/Therapeutic Interface

Room | 259B, Level 2

This session will profile the newest technologies in personalized medicine and how they will fit into future health care models. Can new technologies utilizing dynamic biomarkers, wearables, bioinformatics and multi-omics help justify the case for new therapeutic strategies or ease the regulatory and reimbursement pathway?

  • Moderator | Alice Jacobs, M.D., Advisor, Third Rock Ventures; Entrepreneur-in-Residence, Caltech
    • Robbie Barbero, Ph.D., Chief Business Officer, Ceres Nanosciences
    • Adam Marsh, Ph.D., Chief Scientific Officer, Genome Profiling LLC
    • Jennifer Van Eyk, Ph.D., Director, Advanced Clinical Biosystems Research Institute, co-Director, Precision Health, Cedars Sinai Medical Center

Alxerion Biotech Corporation’s Press Conference

Bio International Convention

Tuesday, June 5 at 9:30 AM in Room 153B

http://Alxerion.com

“Alxerion is the Leader in Exosome Drug Delivery Systems and New Drug Development”

Dr. Elazer Edelman, M.D., Ph.D., F.A.C.C. 

Director MIT IMES and the Harvard-MIT Biomedical Engineering Center

• Announcement of a new breakthrough program for Rare Pediatric Brain Cancers now under development at MIT.

• New concrete results in our Lung Cancer and Solid Sarcoma Cancer drug development programs.

• Video:  Project Darwin-Larmark Argentina expeditions, which to date have discovered over 350,000 exosomes and small RNA and small DNA sequences and enzymes from plants, fungi, algae, microorganisms and insects.

3 New Expeditions announced for: Tierra del Fuego Archipelago, Antartica, The Iberian Estuaries, and Misiones, Amazon Rainforest

• Alxerion’s Partnership with the Massachusetts Institute of Technology and our rapidly expanding pipeline.

Presentors:

• Dr. Elazer Edelman, M.D., Ph.D., F.A.C.C.
Newly appointed director of MIT IMES (Massachusetts Institute of Technology’s Institute for Medical Engineering and Science) and Director of the Harvard-MIT Biomedical Engineering Center (the Edelman Lab)

• Dr. Mercedes Balcells, Ph.D., Principal Research Scientist at MIT’s Instituted for Medical Engineering and Science.

• Dr. Javier Pedreño, M.D., Ph.D., Alxerion Biotech’s Founder and CEO and Scholar Professor at MIT

 I have attached the ALXERION’S EXOSOME BASED TECHNOLOGIES – non-confidential information document for your convenience

BioProcess Theater – Final Agenda (2018 BIO International Convention)

Brian C. sent you a message: “BioProcess Theater – Final Agenda“

 

Make room in your schedule to visit the BioProcess Theater, located at the heart of the BioProcess Zone (booth #375)

The BioProcess Theater is a complimentary, 3-day event delivering the latest science, technologies and trends impacting biopharmaceutical research, development and manufacturing.  Two main presentation tracks focus on emerging therapies and emerging technologies.

View the full BPI Theater agenda:

http://www.bioprocessintl.com/wp-content/uploads/2018/06/BPI-Theater-2018-print-2.pdf  

 

BIO 2018 Program Highlights

Find full information about sessions and speakers in myBIO.

Don’t miss these premier sessions featuring thought leaders and executives from top biotech and pharma companies, and influential keynote speakers.

Add these sessions to your personalized myBIO agenda!

 

BIO 2018 Session Tracks:

Biofuels icon Biofuels & Renewable Chemicals

BrainHealth Icon Brain Health – Sponsored by Sage Therapeutics

Business Development Icon Business Development & Finance – Sponsored by WilmerHale

Corporate best practices Corporate Best Practices & Leadership

DigitalHealth Icon Digital Health

EmergingOpp Icon Emerging Opportunities in Global Markets – Sponsored by Amgen

gene editing track Genome Editing

InfectiousDisease Icon Infectious Diseases & Vaccines – Sponsored by GlaxoSmithKline

IntellectualProperty Icon Intellectual Property – Sponsored by Biogen

Food&Ag Icon Modern Agriculture Innovation – Sponsored by BIO Food & Agriculture Section Governing Board

NextGeneration Icon Next Generation Biotherapeutics

Oncology Icon Oncology  – Sponsored by Bristol-Myers Squibb

one health icon One Health – Sponsored by BIO Food & Agriculture Section Governing Board

opiod track icon Opioids: Changing the Paradigm on Treating Pain and Addiction

Orphan Icon Orphan & Rare Diseases – Sponsored by CSL Behring & Retrophin

PersonalMed Icon Personalized Medicine & Diagnostics – Sponsored by Thermo Fisher Scientific

RegScience Icon Regulatory Innovation 

TranslationalResearch Icon Translational Research  – Sponsored by Clarivate Analytics

Value Icon Value, Patient Access, & Reimbursement – Sponsored by Amgen, Celgene, Syneos Health, and UCB

Interested in Sponsoring Thought Leadership? Contact us at exhibit@bio.org.

BIO Executive Training Programs

BIO’s Executive Training Courses and Entrepreneurship Bootcamp are designed to train and educate business development individuals who are making deals that drive the biotechnology industry. Courses are taught by experienced business development professionals from leading pharmaceutical and biotechnology firms, and experts in law and public relations.

Business Development Fundamentals

Advanced Business Development

Product & Company Valuation Course

Negotiations and Strategic Decision Making

Entrepreneurship Boot Camp

*Executive Training Programs require additional registration.

Other Education Opportunities:

 BioBriefing:Biotech for the Non-Scientist
BioBriefing is a one-day, fast-paced course focused on the science driving today’s hottest biopharma innovations. Engage more effectively with industry leaders at BIO2018 by learning how therapeutic antibodies, RNA therapies, gene therapies, and immunotherapies fight disease and save lives. Learn from an industry expert who knows the technology, products, and companies. Click here to view the agenda and register for BioBriefing. Separate pre-registration and payment are required for this BIO 2018 affiliate event.

Strategic Commercialization Within Biopharma
Strategic Commercialization Within Biopharma is an intensive course focused on the major strategic considerations and tactics integral to successful commercialization within biopharma. Discussion points focus on practical concepts, applications, and tools that help participants effectively build and implement plans and tactics to address the needs of multiple stakeholders in the creation of reimbursable innovation.Click here to view the agenda and register for Strategic Commercialization Within Biopharma. Separate pre-registration and payment are required for this BIO 2018 affiliate event.

Questions? Contact Sheila Wagner at 410.377.4429 or wagner@biotechprimer.com.

BIO 2018 Program Committee:

Thank you to the 2018 BIO International Convention Program Committee for their devoted efforts in creating a world-class education program. The Committee meets on a continuing basis to determine the most cutting edge topics and speakers, and is led by Program Chairs and supported by numerous individuals in all sectors of biotechnology.

For more insight into the educational planning process, check out this exclusive blog post written by former BIO Program Committee Co-Chair, Rob Wright, Chief Editor of Life Science Leader.

SOURCE

http://htl.li/zh7C30jL4kF

BIO 2018 Schedule

PRINT SCHEDULE

Arrive Sunday and Stay Until Friday!

Take full advantage of BIO 2018! Partnering and Education kick off on Monday, and the BIO Exhibition opens Tuesday morning following our first keynote. For more information about fun activities happening at the Boston Convention & Exhibition Center, checkout our Networkingpage!

*Schedule as of May 8, 2018 and subject to change.

 

REGISTER NOW

 

Read Full Post »

Retweets, Likes of Tweets by @AVIVA1950 @pharma_BI on May 8, 2018 for 12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott, Cambridge @USAIC #USAIC2018

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management on May 9, 2018| Leave a Comment »

Retweets, Likes of Tweets by @AVIVA1950 @pharma_BI on May 8, 2018 for 12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott,  Cambridge

@USAIC #USAIC2018

Curator: Aviva Lev- Ari, PhD, RN

 

Re-Tweets of MY TWEETS: via

@pharma_BI

@AVIVA1950

for 12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott Cambridge

@USAIC

#USAIC2018

 

Stephen J Williams Retweeted your Tweet

 

Aviva Lev-Ari @AVIVA1950

Dr. David Goldstein, Director, Institute for Genomic Medicine, Columbia University Medical Center Clinical Trials in AD are very expensive collection of Data of AD populations for subgroups of Patients: Epilepsy vs AD Heterogeneity of AD @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Aviva Lev-Ari @AVIVA1950

SYNOPSIS @USAIC #USAIC2018 by @pharma_BI @AVIVA1950 for 12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott Cambridge https://pharmaceuticalintelligence.com/2018/01/18/12th-annual-us-india-biopharma-healthcare-summit-may-8-2018-marriott-cambridge/ … via @Pharma_BI

 

Aviva Lev-Ari @AVIVA1950

Dr. Meeta Chatterjee, Head, Business Strategy & Operations, Business Development & Licensing, Merck Research Labs Biomarkers as surugate for Outcomes reduce cost of drug development very expensive @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Aviva Lev-Ari @AVIVA1950

@SteliosPapadopoulos @Biogen Investors in Public Companies 80s Biotech @biogen @Genzyme @Amgen @Genetech in 90s @MedicinalChemistry Disappointment 2000-2010, Excitement 2015 on investment is generously @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Aviva Lev-Ari @AVIVA1950

Academic Young entrepreneurs How the split of the rewards determined between the Academic institutions and the Investor? @AnsbertGadicke in China and in The US that definition of rewards is very different. @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Aviva Lev-Ari @AVIVA1950

BioParma Innovation + @AffordablePrice Measurable #MedicalVALUE Drivers of Positive return on R&D: #Payers, #Genomics, #smartmoney, #sophisticatedconsumers of messy #data identify UNDIAGNOZED Patients @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Aviva Lev-Ari @AVIVA1950

Academic Young entrepreneurs How the split of the rewards determined between the Academic institutions and the Investor? #AnsbertGadicke in CHina and in The US that definition of rewards is very different. @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Aviva Lev-Ari @AVIVA1950

@BruceChabner @MGH@HMS @DanaFarber they CREATED the Diagnostics Industry via Genomics pioneering testing and linking to therapy Most of the World does not have ACCESS to #Diagnostics for #PatientSelection @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Aviva Lev-Ari @AVIVA1950

#PhilipRowlands, Head of the Oncology Therapeutic Area Unit, @Takeda Pharmaceuticals Oncology got MOST investment by Pharma assays challenge of Resistence, how prioritization of combination therapy @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Aviva Lev-Ari @AVIVA1950

Panel on Investment: @AnsbertGadicke, Founder & Managing Director @MPM Capital @SteliosPapadopoulos, Chairman @Biogen @TsutomuUne, Senior Corporate Advisor, @GCACorporation Moderator: @WilliamChin, Professor of Medicine, Emeritus @HMS @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Database Integration Retweeted your Tweet

Aviva Lev-Ari @AVIVA1950

@ShahramEbadollahi #IBM @Watson #blockchain #AI is foundational @ColinHill, Chairman & CEO, @GNSHealthcare believes in digitization in Healthcare #BigData used for #repurposing #drugdevelopment and new #drugcombinations development @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Albert Boxler and Logan Stewart followed you

Jerome Gels liked your Tweet

Aviva Lev-Ari @AVIVA1950

BioParma Innovation + @AffordablePrice Measurable #MedicalVALUE Drivers of Positive return on R&D: #Payers, #Genomics, #smartmoney, #sophisticatedconsumers of messy #data identify UNDIAGNOZED Patients @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Eliances Community liked your Tweet

@SteliosPapadopoulos @Biogen Investors in Public Companies 80s Biotech @biogen @Genzyme @Amgen @Genetech in 90s @MedicianlChemistry Disappointment 2000-2010, Excitement 2015 on investment is generously @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Zos liked your reply

Aviva Lev-Ari @AVIVA1950

@StevenPaul CEO @VoyagerTherapeutics #Bipolar #Schizophrenia much development of techniques and methodologies but these diseases are not well known, yet new cycle of development on its way @USAIC #USAIC2018 @pharma_BI @AVIVA1950

Cris De Luca liked your Tweet

Aviva Lev-Ari @AVIVA1950

@MathaiMammen @JnJ Emphasize Disease vs Organizational assignment of science space is crucial hiring people with conviction @MichaelEhlers @Biogen BEST people for Science bench @AndrewPlump @Takeda all efforts on PARTNERSHIPS and culture @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Genomics Edtech Retweeted your Tweet

Aviva Lev-Ari @AVIVA1950

BioParma Innovation + @AffordablePrice Measurable #MedicalVALUE Drivers of Positive return on R&D: #Payers, #Genomics, #smartmoney, #sophisticatedconsumers of messy #data identify UNDIAGNOZED Patients @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

C The Crypto Fox, Bharat Ghankutkar and GNS Healthcare liked your Tweet

Aviva Lev-Ari @AVIVA1950

@ShahramEbadollahi #IBM @Watson #blockchain #AI is foundational @ColinHill, Chairman & CEO, @GNSHealthcare believes in digitization in Healthcare #BigData used for #repurposing #drugdevelopment and new #drugcombinations development @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Cash For Your Warhol liked your Tweet

Aviva Lev-Ari @AVIVA1950

#VijayChandru, Chairman, @StrandLifeSciences Cost compression Data scientists cooperation on Health IT US and India model @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Crypto Goddess 🙂 liked your Tweet

Aviva Lev-Ari @AVIVA1950

#Blockchain platform decision medicine drugs, #AI leverage data already existing find new dedication from data collected in the past @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Sarah Morgan liked your reply

Aviva Lev-Ari @AVIVA1950

@JonathanEpstein @UPenn collaboration with 200 Novartis employees on site at the Medical School Clinical Trial and Manufacturing Cell-based therapies OUTSTANDING Clinicians kept the patient alive during the drug development immunetherapy @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Nate Agapi and Justin Farrell followed you

 

Rubeena Qurashi liked your Tweet

Aviva Lev-Ari @AVIVA1950

Discovery to Commercialization – Data is Fragmented across institutions Diabetes Patients had higher risk for CVD in comparison to Obese Patient non-Diabetes – that data to confirm and monitor was not integrated. @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Cash For Your Warhol liked your Tweet

Aviva Lev-Ari @AVIVA1950

#NeuroDiseases Panelists: @AlfredSandrock @Biogen @DavidGoldstein @Columbia @MaurizioFava @HMS @MeetaChatterjee @Merck @StevenPaul @Voyager @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Georgia Mitsi and USAIC Retweeted your reply

Aviva Lev-Ari @AVIVA1950

@JonathanEpstein @UPenn collaboration with 200 Novartis employees on site at the Medical School Clinical Trial and Manufacturing Cell-based therapies OUTSTANDING Clinicians kept the patient alive during the drug development immunetherapy @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Georgia Mitsi liked your reply

Aviva Lev-Ari @AVIVA1950

@JonathanEpstein @UPenn collaboration with 200 Novartis employees on site at the Medical School Clinical Trial and Manufacturing Cell-based therapies OUTSTANDING Clinicians kept the patient alive during the drug development immunetherapy @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

 

MY TWEETS: via

@pharma_BI

@AVIVA1950

at for 12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott Cambridge

@USAIC

#USAIC201

2 replies 32 retweets 49 likes

 

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

SYNOPSIS @USAIC #USAIC2018 by @pharma_BI @AVIVA1950 for 12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott Cambridge https://pharmaceuticalintelligence.com/2018/01/18/12th-annual-us-india-biopharma-healthcare-summit-may-8-2018-marriott-cambridge/ … via @Pharma_BI

 

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@AndrewPlump Chief Medical and Scientific Officer @Takeda Role of #AcademicInstitutions in Innovation and R&D?

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@VijayChandru, Chairman, @StrandLifeSciences Cost compression Data scientists cooperation on Health IT US and India model @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@ShahramEbadollahi @IBMWatson Access of Patient data, clinical Trial data, medical record data Tested on a Bitcoin platform using encryption as a Trusted distributed data architecture system @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@ShahramEbadollahi @IBMWatson #AI #Bitcoin is a platform for integration of all the records for Watson platform transaction – establish TRUST based on the cryptography of the system consent to share data FDA and CDC as Partner to TEST data @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

Technology Platforms @ChrisBenko, Co-Founder & CEO @KoneksaHealth @ColinHill CEO @GNSHealthcare @PeterMueller, Chairman, @BioXcelTherapeutics @ShahramEbadollahi @IBM Watson Health Group, IBM @VijayChandru, Chairman @StrandLifeSciences @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@SusanHockfield ex-President @MIT Thesis is a source of ideas @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@GeorgeDaley Dean @HMS PhD Program Faculties spend Sabbaticals in Industry BIOLOGY IS ADVANCING FAST NEW PROGRAMS FOR HTERAPIES @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Like

 

 

View Tweet activity

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@SusanHockfield ex-President @MIT the INTELLIGENT WEST #AI # Radiology interpretation @ReginaBarzilay revising curriculum to reinvent the FIELD basket of problems industry people on Campus searching @MIT Basket of experiment & ideas @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@GeorgeDaley Dean @HMS Tools penetration systems going back and forth between models Interdisciplinary institutes, @Harvard Centers for research Projects do not get advanced enough to interest VCs 100 faculties mroject not advanced enough @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@SusanHockfield ex-President @MIT Foundations MIT faculties go back and forth to Industry Research in Educ Institution, purpose of Univ different that Top-DOwn Org producing @MIT #engineering and #BiologicalSciences are placed together @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@GeorgeDaley Dean @HMS Science happens faster, ecosystem In 15 yrs different system rethink new ways 35 years of incubation accelerate process invest in regulatory change the Game to eb cheaper better faster invest in new Initiative @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

Fireside Chat: @GeorgeDaley Dean @HMS @SusanHockfield President Emerita & Professor of Neuroscience @MIT Moderator: @AndrewPlump Chief Medical and Scientific Officer @Takeda @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

Academic Young entrepreneurs How the split of the rewards determined between the Academic institutions and the Investor? @AnsbertGadicke in CHina and in The US that definition of rewards is very different. @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@AnsbertGadicke, Founder & Managing Director, MPM Capital Invest in combinations therapy in one vial several times cheaper than each agent alone @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@SteliosPapadopoulos, Chairman @Biogen Studies on #Prevention – CVD Endpoint right drug to get to endpoint by clinical trials #Vaccines: validate science that it can be done @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@WilliamChin, Professor of Medicine, Emeritus, Harvard Medical School Notion A1C took decades to develop @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@TsutomuUne, Senior Corporate Advisor @GCA Corporation Need to care for ELderly population should direct the investment – we started with therapy then prevention @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@AnsbertGadicke, Founder & Managing Director @MPM Capital Academic founders of start ups – innovations from Academia @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@AnsbertGadicke, Founder & Managing Director @MPMCapital Investment of private funds $50Million in a start up on average stay away from Capital market @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@SteliosPapadopoulos, Chairman @Biogen New compounds is the name of the game for pipeline of drugs @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

 

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@TsutomuUne, Senior Corporate Advisor, @GCACorporation invest in buying the opportunity to participate @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@AnsbertGadicke @MPMCapital New Directions: Own money for IMPACT module invest in young investigators investment in Underdeveloped countries to offer access to drugs @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@SteliosPapadopoulos @Biogen Investors in Public Companies 80s Biotech @biogen @Genzyme @Amgen @Genetech in 90s @MedicianlChemistry Disappointment 2000-2010, Excitement 2015 on investment is generously @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

Panel on Investment: @AnsbertGadicke, Founder & Managing Director @MPM Capital @SteliosPapadopoulos, Chairman @Biogen @TsutomuUne, Senior Corporate Advisor, @GCACorporation Moderator: @WilliamChin, Professor of Medicine, Emeritus @HMS @USAIC #USAIC2018 @pharma_BI @AVIVA1950

Translate Tweet

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@VictoriaRichon, President & CEO @Ribon Therapeutics @KurtStoeckli @Glen Pharmaceuticals – EARLY detection continues to be the calprit of Therapy Outcome @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@VictoriaRichon, President & CEO, @Ribon Therapeutics Biomarker development for use in assignment of Patients to Clinical Trials @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@BruceChabner @MGH@HMS @DanaFarber they CREATED the Diagnostics Industry via Genomics pioneering testing and linking to therapy Most of the World does not have ACCESS to #Diagnostics for #PatientSelection @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

Reimbursement for Diagnostics @PhilipRowlands @Takeda Oncology is very competitive next generation is combination therapy – which one to own @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@RakeshJain @MGH @HMS Biomarkers needs for the micro-environment of the Tumors @KurtStoeckli #PrecisionTherapy will be key for cost efficiencies @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@BruceChabner @MGH @HMS – DRUG-Based Biomarkers – circulating DNA, Exosomes moving directly to Clinical Trials @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@PhilipRowlands, Head of the Oncology Therapeutic Area Unit, @Takeda Pharmaceuticals Oncology got MOST investment by Pharma assays challenge of Resistence, how prioritization of combination therapy @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@RakeshJain, #TumorBiology, @MGH Cancer Center @HMS Immuno supression caused by Hypoxia, improve oxigenation buy prescription of antihypertension drugs, stinulate the innume system checkpoint blockers @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

#Oncology Panelists: Moderator: @RajuKucherlapati @HMS @BruceChabner @MGH @HMS @KurtStoeckli @Glenmark @PhilipRowlands @Takeda @VictoriaRichon @RibonTherapeutics @RakeshJain @MGH @HMS @USAIC #USAIC2018 @pharma_BI @AVIVA1950

Translate Tweet

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@MathaiMammen @JnJ Emphasize Disease vs Organizational assignment of science space is crucial hiring people with conviction @MichaelEhlers @Biogen BEST people for Science bench @AndrewPlump @Takeda all efforts on PARTNERSHIPS and culture @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@MichaelEhlers, Head of Research & Development, Biogen moved from Pfizer to Biogen HUMAN BIOLOGY across the board scientific clinical judgement scientists that scrutinize data and are skeptical are reluctant to be Sales @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@AndrewPlump, Chief Medical and Scientific Officer @Takeda Pharmaceuticals out of 12 drugs introduced in decade 4 got to market all were acquisitions transformation 2013 restructuring lab updates new pipeline – stabilize stage @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

Drug Discovery: @AndrewPlump, Chief Medical and Scientific Officer, @Takeda @MathaiMammen, Global Head of R&D, @Janssen Pharmaceutical- JnJ @MichaelEhlers, Head of Research & Development @Biogen Moderator: @Martin Mackay CEO @Rallybio @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

BioParma Innovation + @AffordablePrice Measurable #MedicalVALUE Drivers of Positive return on R&D: #Payers, #Genomics, #smartmoney, #sophisticatedconsumers of messy #data identify UNDIAGNOZED Patients @USAIC #USAIC2018 @pharma_BI @AVIVA1950

0 replies 2 retweets1 like

  1. Aviva Lev-Ari‏ @AVIVA195021h21 hours ago

More

BioPharma: An Extraordinary BioPharma Disruption @AjayDhankhar, Senior Partner, @McKinsey @SastryChilukuri @McKinsey Big-4 Disruptions: #Aging #Urbanization #Globalization #TechnoAcceleration: #IT #Buildingblocks #Robotics #NewEnergy @USAIC #USAIC2018 @pharma_BI @AVIVA1950

Translate Tweet

  1. Aviva Lev-Ari‏ @AVIVA195021h21 hours ago

More

@ShahramEbadollahi #IBM @Watson #blockchain #AI is foundational @ColinHill, Chairman & CEO, @GNSHealthcare believes in digitization in Healthcare #BigData used for #repurposing #drugdevelopment and new #drugcombinations development @USAIC #USAIC2018 @pharma_BI @AVIVA1950

0 replies1 retweet3 likes

  1. Aviva Lev-Ari‏ @AVIVA195022h22 hours ago

More

#Blockchain platform decision medicine drugs, #AI leverage data already existing find new dedication from data collected in the past @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195022h22 hours ago

More

#VijayChandru, Chairman, @StrandLifeSciences Cost compression Data scientists cooperation on Health IT US and India model @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195022h22 hours ago

More

#ShahramEbadollahi @IBMWatson Access of Patient data, clinical Trial data, medical record data Tested on a Bitcoin platform using encryption as a Trusted distributed data architecture system @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195022h22 hours ago

More

#ShahramEbadollahi @IBMWatson #AI #Bitcoin is a platform for integration of all the records for Watson platform transaction – establish TRUST based on the cryptography of the system consent to share data FDA and CDC as Partner to TEST data @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195022h22 hours ago

More

Technology Platforms #ChrisBenko, Co-Founder & CEO @KoneksaHealth #ColinHill CEO @GNSHealthcare #PeterMueller, Chairman, @BioXcelTherapeutics #ShahramEbadollahi @IBM Watson Health Group, IBM #VijayChandru, Chairman @StrandLifeSciences @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

Academic Young entrepreneurs How the split of the rewards determined between the Academic institutions and the Investor? #AnsbertGadicke in CHina and in The US that definition of rewards is very different. @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#SteliosPapadopoulos focus on DISTRUCTIVE treatment price control, regulation will impact investment @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#AnsbertGadicke, Founder & Managing Director, MPM Capital Invest in combinations therapy in one vial several times cheaper than each agent alone @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#SteliosPapadopoulos, Chairman @Biogen Studies on #Prevention – CVD Endpoint right drug to get to endpoint by clinical trials #Vaccines: validate science that it can be done @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#William Chin, Professor of Medicine, Emeritus, Harvard Medical School Notion A1C took decades to develop @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#TsutomuUne, Senior Corporate Advisor @GCA Corporation Need to care for ELderly population should direct the investment – we started with therapy then prevention @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#AnsbertGadicke, Founder & Managing Director @MPM Capital Academic founders of start ups – innovations from Academia @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#AnsbertGadicke, Founder & Managing Director @MPMCapital Investment of private funds $50Million in a start up on average stay away from Capital market @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#SteliosPapadopoulos, Chairman @Biogen New compounds is the name of the game for pipeline of drugs @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#TsutomuUne, Senior Corporate Advisor, @GCACorporation invest in buying the opportunity to participate @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#AnsbertGadicke @MPMCapital New DIrections: Own money for IMPACT module invest in young investigators investment in Underdeveloped countries to offer access to drugs @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#SteliosPapadopoulos @Biogen Investors in Public Companies 80s Biotech @biogen @Genzyme @Amgen @Genetech in 90s @MedicianlChemistry Disappointment 2000-2010, Excitement 2015 on investment is generousely @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195024h24 hours ago

More

Panel on Investment: @AnsbertGadicke, Founder & Managing Director @MPM Capital #SteliosPapadopoulos, Chairman @Biogen @TsutomuUne, Senior Corporate Advisor, @GCACorporation Moderator: @WilliamChin, Professor of Medicine, Emeritus @HMS @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195024h24 hours ago

More

@AndrewPlump, Chief Medical & Scientific Officer, @Takeda Pharmaceuticals In the Past Cancer was a death sentence NOT any more, we see therapy and cure in Oncology @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195024h24 hours ago

More

#VictoriaRichon, President & CEO @Ribon Therapeutics #KurtStoeckli @Glen Pharmaceuticals – EARLY detection continues to be the calprit of Therapy Outcome @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195024h24 hours ago

More

@RakeshJain, @MGH @HMS IF 85% of blood vessels in tumor are collapsed (hypoxia) how do you deliver drugs to the tumor?? @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195024h24 hours ago

More

#Diagnostics is not a viable model for #Investors unless the reimbursement will change the process for diagnostics approval is like of drugs @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195024h24 hours ago

More

#VictoriaRichon, President & CEO, @Ribon Therapeutics Biomarker development for use in assignment of Patients to Clinical Trials @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195024h24 hours ago

More

#BruceChabner @MGH@HMS @DanaFarber they CREATED the Diagnostics Industry via Genomics pioneering testing and linking to therapy Most of the World does not have ACCESS to #diagnostics #Diagnostics for #PatientSelection @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195024h24 hours ago

More

Reimbursement for Diagnostics #PhilipRowlands @Takeda Oncology is very competitive next generation is combination therapy – which one to own @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195024h24 hours ago

More

#RakeshJain @MGH @HMS Biomarkers needs for the micro-environment of the Tumors #KurtStoeckli #PrecisionTherapy willl be key for cost efficiencies @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

Dr. Kurt Stoeckli, President and Chief Scientific Officer, Glenmark Pharmaceuticals – cost effectiveness by clinical trial design and biomarkers @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

#BruceChabner @MGH @HMS – DRUG-Based Biomarkers – circulating DNA, Exosomes moving directly to Clinical Trials @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

#PhilipRowlands, Head of the Oncology Therapeutic Area Unit, @Takeda Pharmaceuticals Oncology got MOST investment by Pharma assays challenge of Resistence, how prioritization of combination therapy @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@KurtStoeckli, President and Chief Scientific Officer, Glenmark Pharmaceuticals Translational Experiment on going origin of the cells, microenvironment, immuno science models @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@VictoriaRichon, President & CEO @RibonTherapeutics DO we have the bIomarkers, do we ahve the right Trial, How to bring new therapies – agree Biomarkers are kEY @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

Dr. Kurt Stoeckli, President and Chief Scientific Officer, Glenmark Pharmaceuticals Testing the right combination therapy is critical @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

Dr. Bruce Chabner, Director of Clinical Research, Mass General Hospital Cancer Center/Harvard Medical School told historic milestory in Oncology Therapy @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

#RakeshJain, #TumorBiology, @MGH Cancer Center @HMS Immuno supression caused by Hypoxia, improve oxigenation buy prescription of antihypertension drugs, stinulate the innume system checkpoint blockers @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

#Oncology Panelists: Moderator: #RajuKucherlapati @HMS #BruceChabner @MGH @HMS #KurtStoeckli @Glenmark #PhilipRowlands @Takeda #VictoriaRichon @RibonTherapeutics #RakeshJain @MGH @HMS @USAIC #USAIC2018 @pharma_BI @AVIVA1950

Translate Tweet

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@AlfredSandrock #CMO @Biogen Sensors better than neuro-cognitive testing and assessment of cognition @MaurizioFava @HMS The ALL OF US One Million Volunteer is very promising for research @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@DavidGoldstein, Director, Institute for Genomic Medicine, @Columbia University Medical Center Accelerate getting Knowledge of the disease, CF biology was known in AD combination of Amyloid in MRI Imaging and Genomics in combination @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@MaurizioFava @HMS Leverage Big Data very important in Clinical Trial Design, Biomarkers Using #ML on Data we are close best minds are applied to #AI Universities must become user-friendly to Industry for Clinical Trials @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@StevenPaul @VoyagerTherapeutics SLOWING the disease by 6 years save 50% of the dying from disease @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

Moderator: @SteveUden, Co-Founder, @Rallybio Identify Early disease, @StevenPaul @VoyagerTherapeutics Biomarkers: if Amyloid at age 40 – progression to AD predicted, TAU predicts progression of AD @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

Dr. David Goldstein, Director, Institute for Genomic Medicine, Columbia University Medical Center Clinical Trials in AD are very expensive collection of Data of AD populations for subgroups of Patients: Epilepsy vs AD Heterogeneity of AD @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

Dr. Meeta Chatterjee, Head, Business Strategy & Operations, Business Development & Licensing, Merck Research Labs Biomarkers as surugate for Outcomes reduce cost of drug development very expensive @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@StevenPaul, President and Chief Executive Officer, Voyager Therapeutics CNS is not to be compare with antiCHolesterol DIsease, Ameloid is necessary not sufficient @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@MeetaChatterjee, Head, Business Strategy & Operations, Business Development & Licensing, @Merck In ImmunoOncology great success BUT in Dimentia and Alzheimer’s Disease NO success to compare @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@StevenPaul CEO @VoyagerTherapeutics #Bipolar #Schizophrenia much development of techniques and methodologies but these diseases are not well known, yet new cycle of development on its way @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@DavidGoldstein #GenomicMedicine @Columbia CNS diseases: ALS, Epilepsy NOT only and NOT primarily Genomics Focus on Disease but pathways, proteins @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

Early Clinical Trials in #MultitpleSclerosis Breakthrough is using MRI for disease progression prediction @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

#NeuroDiseases Panelists: @AlfredSandrock @Biogen @DavidGoldstein @Columbia @MaurizioFava @HMS @MeetaChatterjee @Merck @StevenPaul @Voyager @USAIC #USAIC2018 @pharma_BI @AVIVA1950

Translate Tweet

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@JonathanEpstein Students are in need for internships with Industry and develop entrepreneurships @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

DIscovery to Commercialization – Data is Fragmented across institutions Diabetes Patients had higher risk for CVD in comparison to Obese Patient non-Diabetes – that data to confirm and monitor was not integrated. @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@ChasBountra @Oxford Accessing in the UK across all Academia opening resources: Goventment funds, Takeda helps in resources needed for integration of sources WHile in Academia Access across institutions is easier @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

In India explosion Hospitals adding Bioinformatics and Big Data Analytics, Databases on Infectious Diseases. Data Mining Pfizer is surveying disease data @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@ChasBountra Talking on MPACT, drug discovery the role of Academia is NOT ro replicate the excellence existing in Pharma, in Academia basic sciencec innovations to lead @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

Partnership with academia to enrich the early pipeline with new drugs Transformation on matters of science no internal expertise exist @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@JonathanEpstein @UPenn collaboration with 200 Novartis employees on site at the Medical School Clinical Trial and Manufacturing Cell-based therapies OUTSTANDING Clinicians kept the patient alive during the drug development immunetherapy @USAIC #USAIC2018 @pharma_BI @AVIVA1950

0 replies 2 retweets 2 likes

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@SridaranNatesan major role played by New Prime Minister @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

In India major shift from publications in Journals to funding start ups, India Industry became bold, interaction with academia outside of India Sweden, Stanford, Boston – @JoslinClinic – Formulation Vaccine India Tech Transfer was a problem @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

@JonathanEpstein #CSO @UPenn Success of the Process wish to see results in our Life time IMPACT of innovations @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@JimGlasheen @UMMS Transfer Office has challenges of responsiveness to Faculty @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@NirmalKumarGanguly, President, @ApolloHospitals promising relationships with Academia changing mind set different organizational culture @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@ChasBountra, Chief Scientist, Structural #Genomics Consortium @Oxford discover NOVEL #reagents given to #Academia and #Pharma @USAIC #USAIC18 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

Industry-Academic Research Partnerships Moderator: @JuanHarrison @Takeda #Industry #BigPharma #Academia STORIES @ChasBountra @Oxford @JimGlasheen @UMass @JonathanEpstein @UPenn @NirmalKumarGanguly @ApolloHospitals @SridaranNatesan @Sanofi @USAIC #USAIC18 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@AndrewPlump, Chief Medical & Scientific Officer, @Takeda #Pharmaceuticals Government Challenges in India active is providing access and affordable #HealthCare @USAIC #USAIC18 @pharma_BI @AVIVA1950

Aviva Lev-Ari‏ @AVIVA1950 May 7

More

12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott Cambridge @USAIC #USAIC18 @pharma_BI @AVIVA1950 https://pharmaceuticalintelligence.com/2018/01/18/12th-annual-us-india-biopharma-healthcare-summit-may-8-2018-marriott-cambridge/ … via @Pharma_BI

Read Full Post »

12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott Cambridge

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media on January 18, 2018| Leave a Comment »

12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott Cambridge

Reporter: Aviva Lev-Ari, PhD, RN

http://usaindiachamber.org/speaker.php

@USAIC

#USAIC2018

 

Announcement

Aviva Lev-Ari, PhD, RN,

Founder and Director of LPBI Group will be in attendance covering the event in REAL TIME

@pharma_BI

@AVIVA1950

 

All TWEETS from LPBI’s Twitter.com handles at

@USAIC

#USAIC2018

by

@pharma_BI

@AVIVA1950

BioPharma & Healthcare Summit – May 8, 2018

Chair and Emcee – Dr. Andrew Plump, Chief Medical & Scientific Officer, Takeda Pharmaceuticals

Time Topic
8-45 AM – 9-10 AM Registration and Networking
9-10 AM – 9-25 AM Welcome address: Karun Rishi, President, USA-India Chamber of Commerce (USAIC)

Opening comments: Dr Andrew Plump, Chief Medical & Scientific Officer, Takeda Pharmaceuticals
9-25 AM – 10-15 AM Panel Discussion: Industry-Academic Research Partnerships

Panelists:

  • Dr. Chas Bountra, Chief Scientist, Structural Genomics Consortium Oxford, University of Oxford
  • Dr. Jim Glasheen, Executive Vice Chancellor, University of Massachusetts Medical School
  • Dr. Jonathan Epstein, Executive Vice Dean & Chief Scientific Officer, Perelman School of Medicine, University of Pennsylvania
  • Dr. Nirmal Kumar Ganguly, President, Apollo Hospitals Educational & Research Foundation
  • Dr. Sridaran Natesan, Head – Strategic Initiatives & Scientific Relations, R&D, Sanofi North America

Moderator:
Juan Harrison, Vice President, Head of Strategic Academic Alliances, Takeda Pharmaceuticals
10-15 AM – 11-05 AM Panel Discussion: Neuro Diseases                                                                                                          

Panelists:

  • Dr. Alfred Sandrock, Executive Vice President & Chief Medical Officer, Biogen
  • Dr. David Goldstein, Director, Institute for Genomic Medicine, Columbia University Medical Center
  • Dr. Maurizio Fava, Associate Dean, Clinical & Translational Research, Harvard Medical School
  • Dr. Meeta Chatterjee, Head, Business Strategy & Operations, Business Development & Licensing, Merck Research Labs
  • Dr. Steven Paul, President and Chief Executive Officer, Voyager Therapeutics

Moderator:
Dr. Steve Uden, Co-Founder, Rallybio
11-05 AM -11-35 AM Networking Break
11-35 AM – 12-25 PM Panel Discussion: Oncology

Panelists:

  • Dr. Bruce Chabner, Director of Clinical Research, Mass General Hospital Cancer Center/Harvard Medical School
  • Dr. Kurt Stoeckli, President and Chief Scientific Officer, Glenmark Pharmaceuticals
  • Dr. Philip Rowlands, Head of the Oncology Therapeutic Area Unit, Takeda Pharmaceuticals
  • Dr. Victoria Richon, President & CEO, Ribon Therapeutics
  • Dr. Rakesh Jain, Director, E.L. Steele Laboratory of Tumor Biology,  Mass General Hospital Cancer Center/HMS

Moderator:
Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School
12-25 PM – 1-00 PM Fireside Chat:

  • Dr. Ansbert Gadicke, Founder & Managing Director, MPM Capital
  • Dr. Stelios Papadopoulos, Chairman, Biogen
  • Dr. Tsutomu Une, Senior Corporate Advisor, GCA Corporation

Moderator: 
Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School
1-00 PM – 2-40 PM Luncheon Panel Discussion: Technology Platforms

Panelists:

  • Chris Benko, Co-Founder & CEO, Koneksa Health
  • Colin Hill, Chairman & CEO, GNS Healthcare
  • Dr. Peter Mueller, Chairman, BioXcel Therapeutics
  • Dr. Shahram Ebadollahi, Vice President, Innovations & Chief Scientific Officer, IBM Watson Health Group, IBM
  • Dr. Vijay Chandru, Chairman, Strand Life Sciences

Moderator:
Dr. Ajay Dhankhar, Senior Partner, McKinsey and Company
2-40 PM – 3-15 PM Networking & Tea Break
3-15 PM – 3-35 PM BioPharma: An Extraordinary Disruption

Dr. Ajay Dhankhar, Senior Partner, McKinsey and Company
Sastry Chilukuri, Partner, McKinsey and Company
3-35 PM – 4-30 PM Panel Discussion: Drug Discovery and Development

Panelists:

  • Dr. Andrew Plump, Chief Medical & Scientific Officer, Takeda Pharmaceuticals
  • Dr. Mathai Mammen, Global Head of R&D, Janssen Pharmaceutical- Johnson & Johnson
  • Dr. Michael Ehlers, Executive Vice President and Head of Research & Development, Biogen

Moderator:
Dr. Martin Mackay, Co-Founder and CEO, Rallybio
4-30 PM – 5-05 PM Fireside Chat:

  • Dr. George Daley, Dean, Harvard Medical School
  • Dr. Susan Hockfield, President Emerita & Professor of Neuroscience, Massachusetts Institute of Technology (MIT)

Moderator:
Dr Andrew Plump, Chief Medical and Scientific Officer, Takeda Pharmaceuticals
5-05 PM – 5-10 PM Closing Remarks
5-10 PM – 6-30 PM Cocktails & Networking Reception

*Luncheon Panel Discussion: Lunch will be served at the table at 12:50 PM. Panel will start at 1:40 PM

* Speaker and Timings subject to change

Some of the Speakers and Participants

Dr. Andrew Plump
Chief Medical & Scientific Officer
Takeda Pharmaceuticals
Dr. James Bradner
President
Novartis Institutes for BioMedical Research
Prof. Susan Hockfield
President Emerita
MIT
Dr. Mathai Mammen
Global Head of R&D
Janssen R&D
Dr. Stelios Papadopoulos
Chairman- Biogen
Chairman- Exelixis

Dr. Martin Mackay
Co-Founder
Rallybio
Dr. R.K. Vats*
Additional Secretary
Ministry of Health & Family Welfare
Dr. George Daley
Dean
Harvard Medical School
Sanat Chattopadhyay
President- Merck Manufacturing Division
Merck & Co.
Dr. Steven Paul
President & CEO
Voyager Therapeutics

Dr. Bruce Chabner
Director of Clinical Research
Mass General Hospital Cancer Center
Dr. Eswara Reddy*
Drugs Controller General of India
Ministry of Health & Family Welfare
Dr. William W. Chin
Professor of Medicine, Emeritus
Harvard Medical School
Dr. Alfred Sandrock
Executive Vice President & CMO
Biogen
Dr. Jonathan Epstein
Executive Vice Dean & CSO
Perelman School of Medicine, UPenn

Dr. Chas Bountra
Chief Scientist
Structural Genomics Consortium Oxford
Dr. Katherine Bowdish
Head
Sanofi Sunrise
Dr. Philip Rowlands
Head of the Oncology TAU
Takeda Pharmaceuticals
Dr. Sridaran Natesan 
Vice President- Strategic Initiatives
Sanofi
Jim Gilbert
Senior Partner
Flagship Pioneering

Dr. Jim Glasheen
Executive Vice Chancellor
UMass Medical School
Dr. Steve Hitchcock
Global Head of Research
Takeda Pharmaceuticals
Dr. Victoria Richon
President & CEO
Ribon Therapeutics
Dr. Michael Ehlers
Executive Vice President R&D
Biogen
Prof. Nirmal Kumar Ganguly
Former Director General
ICMR

Dr. Rakesh Jain
Prof. of Tumor Biology
MGH/Harvard Medical School
Dr. Daniel Jay
Dean- Sackler School
Tufts University
Dr. Michael Mendelsohn
Founder & Executive Chairman
Cardurion Pharmaceuticals
Dr. Christiana Bardon
Managing Director
MPM Capital
Dr. Tsutomu Une
Senior Corporate Advisor
GCA Corporation

Dr. Maurizio Fava
Associate Dean for Translational Research
Harvard Medical School
Dr. Peter Mueller
Chairman
BioXcel Therapeutics
Dr. Anthony Muslin
Head of Cardiovascular & Fibrosis Research
Sanofi
Brad Margus
Chief Executive Officer
Cerevance
Dr. Steve Uden
Co-Founder
Rallybio

Dr. Kurt Stoeckli
President & CSO
Glenmark Pharmaceuticals
Dr. Shahram Ebadollahi
Chief Science Officer
IBM Watson Health Group
Dr. Carl Goldfischer
Managing Director
Bay City Capital
Philippe Lopes-Fernandes 
Senior Vice-President
Merck KGaA, Darmstadt, Germany
Dr. Michael Cima
Associate Dean of Innovation
MIT School of Engineering

Benjamin Thorner
Head of Business Dev & Licensing
Merck Research Labs
Dr. Tal Zaks
Chief Medical Officer
Moderna Therapeutics
Dr. Mario Saltarelli
SVP- Early Dev & Neurology
Vertex Pharmaceuticals
Dr. Ole Isacson
Professor of Neurology
Harvard Medical School
Dr. Iman El-Hariry
Chief Medical Officer
ERYTECH

Dr. Raju Kucherlapati
Professor of Genetics
Harvard Medical School
Dr. Kimberly Wagner
President & COO
CiBO Technologies
Dr. Lex H.T. Van der Ploeg
Chief Scientific Officer
Rhythm Pharma
Dr. Christopher Wright
Chief Development Officer
Ironwood Pharmaceuticals
Dr. Iya Khalil
Co-Founder & Exe. Vice President
GNS Healthcare

Juan Harrison
VP, Head of Strategic Academic Alliances
Takeda Pharmaceuticals
Dr. Vijay Chandru
Chairman
Strand Life Sciences
Vikas Sinha
Managing Director
MPM Capital
Dr. David Goldstein
Director-Institute for Genomic Medicine
Columbia University Medical Center
Dr. Birgit Schoeberl
Global Head Modeling & Simulation
Novartis Institutes for BioMed Res.

Dr. Ajay Dhankhar
Senior Partner
McKinsey and Company
Dr. Markus Haeberlein
Head of Discovery
Alkermes
Dr. Ajay Nirula
Vice President-Immunology
Eli Lilly
Dr. Isabel Aznarez
Co-Founder & Head of Biology
Stoke Therapeutics
Dr. Harith Rajagopalan
Co-Founder & CEO
Fractyl

Dr. Christopher Locher
Co-Founder & CEO
Versatope Therapeutics
Colin Hill
Co- Founder & Chairman
GNS Healthcare
Dr. Thomas Schuetz
Co-founder & CEO
Compass Therapeutics
Constantine Chinoporos
Chief Business Officer
Boston Pharmaceuticals
Dr. Frank Bobe
Entrepreneur-in-Residence
Wyss Institute

Sanjiv Patel
President & CEO
Relay Therapeutics
Dr. Rhonda Kaufman
Director
Foresite Capital Management
Dr. Meeta Chatterjee
Head- Business Strategy, BD&L
Merck Research Laboratories
Vinay Ranade
Head of Biosimilars
Reliance Life Sciences
Dr. Robert Copeland
Co Founder & President
Accent Therapeutics

Winston Kung
Chief Operating Officer
PMV Pharma
Dr. Femida Gwadry-Sridhar
Founder & CEO
Pulse Infoframe
Dr. Barry Ticho
Chief Medical Officer
Stoke Therapeutics
Dr. Patrick Anquetil
Chief Executive Officer
Portal Instruments
John Ripple
Chief Executive Officer
Exonics Therapeutics

Dr. James Cassella
Chief Development Officer
Concert Pharmaceuticals
Chris Benko
Co-Founder & CEO
Koneksa Health
Dr. Stefan Scherer
Head Early Dev, Strategy & Innovation
Novartis
Dr. Michael Vasconcelles
Chief Medical Officer
Unum Therapeutics
Jeff Hackman
Chief Operating Officer
Novelion Therapeutics

Read Full Post »

36th Annual J.P. Morgan HEALTHCARE CONFERENCE January 8 – 11, 2018

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital on January 9, 2018| Leave a Comment »

36th Annual J.P. Morgan HEALTHCARE CONFERENCE January 8 – 11, 2018

Reporter: Aviva Lev-Ari, PhD, RN

 

Keynotes

Monday, January 8
healthcare key headshot graphic bill gates
Bill Gates
Co-Chair and Trustee of the
Bill & Melinda Gates Foundation
Tuesday, January 9
Jamie Dimon Headshot
Jamie Dimon
Chairman and Chief Executive Officer,
JPMorgan Chase & Co.
Wednesday, January 10
healthcare key headshot graphic Paul
Paul Begala
Political Analyst and Commentator
for CNN
healthcare key headshot graphic tucker
Tucker Carlson
Host of Tucker Carlson Tonight
and Founder of The Daily Caller
SOURCE

Read Full Post »

Economic Potential of a Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) versus a Cancer Drug in Clinical Trials: CAR-T as a Case in Point, developed by Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017.

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, CANCER BIOLOGY & Innovations in Cancer Therapy, CAR-T, Immune Engineering, Immuno-Oncology & Genomics, Immunotherapy, Intellectual Property, Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough, Interviews with Scientific Leaders, Patent Law in Biotech, Venture Capital on October 4, 2017| Leave a Comment »

Economic Potential of a Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) versus a Cancer Drug in Clinical Trials: CAR-T as a Case in Point, developed by Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017.

Curator: Aviva Lev-Ari, PhD, RN

Article ID #245: Economic Potential of a Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) versus a Cancer Drug in Clinical Trials: CAR-T as a Case in Point, developed by Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017. Published on 10/4/2017

WordCloud Image Produced by Adam Tubman

UPDATED on 2/21/2021

The Announcement of the 2021 Dan David Prize Laureates – YouTube – PRIZE $1MM per Winner for contributors to CAR-T MOA leading to development of immunotherapy anti cancer drugs

  • Prof. Zelig Eshhar – Weitzmann Institute his student Arie S. Belldegrun was CEO at Kate Pharmaceutics sold to Gilead for $12Bil
  • Prof. Carl June of UPenn
  • Steven Rosenberg, PhD, NIH

UPDATED on 10/15/2020

Hooked by the science, Arie Belldegrun joins a group of influentials who believe Dewpoint may have the key to the next big thing in biotech
John Carroll
Editor & Founder
Amir Nashat knew he had years of preclinical work to do when he talked to me at the beginning of 2019 about Dewpoint Therapeutics and its rare focus on the role bimolecular condensates could play in crafting a wide-ranging pipeline of therapeutics.

SOURCE

Hooked by the science, Arie Belldegrun joins a group of influentials who believe Dewpoint may have the key to the next big thing in biotech

The Cambridge, MA-based Dewpoint team, which will now double in size over the next year, doesn’t have a late-stage preclinical program it can shove into the clinic. The biotech is investing in neurodegeneration, cancer, cardiovascular and other areas for a platform that could, eventually, have extensive applications. But asked about a timeline to proof-of-concept data, Nashat frankly estimates that it will take 4-5 years to birth some hard human data. The money should get them through 3 years and a considerable de-risking approach to their preclinical efforts

The CSO is Mark Murcko, an experienced and well known startup player.

Mark Murcko
“When I think about new companies a lot of it is about timing; is it too soon or too late?” Murcko notes enthusiastically in our interview. “Is there enough information available to make you think you can take that and use it toward new drugs? Five years ago it was too early, too nascent.”

Now, Murcko adds, seems like a great time to give this a go.

SOURCE

Polaris’ Amir Nashat pulls together a $60M launch round to back the birth of a new biotech building a drug development platform from scratch

UPDATED on 7/16/2019

Part club, part guide, part landlord: Arie Belldegrun is blueprinting a string of bespoke biotech complexes in global boomtowns — starting with Boston

Part club, part guide, part landlord: Arie Belldegrun is blueprinting a string of bespoke biotech complexes in global boomtowns — starting with Boston

UPDATED on 3/11/2019

At California Central District Court Juno Therapeutics, Inc. et al v. Kite Pharma, Inc. – Multi-party Patent Infringement

At California Central District Court Juno Therapeutics, Inc. et al v. Kite Pharma, Inc. – Multi-party Patent Infringement

UPDATED on 2/6/2019

Gilead takes an $820M hit after axing a Kite CAR-T. Are billions more going to be incinerated?

 

by john carroll — on 
Updated: 

Gilead is writing off its anti-BCMA CAR-T for multiple myeloma, eliminating one of the many efforts focused on that target and driving a big part of the company’s $820 million impairment charge for R&D in the 4th quarter of last year.  But this could just be a taste of what’s to come.

Gilead takes an $820M hit after axing a Kite CAR-T. Are billions more going to be incinerated?

A $12 billion buyout of Kite Pharma in 2017 brought with it the CAR-T therapy Yescarta (axicabtagene ciloleucel) and a foothold in immuno-oncology. But last year’s results make clear that return on that investment will be slow to materialize.

https://www.biopharmadive.com/news/gilead-earnings-q4-investors-trial-readouts/547697/

Buried in among Gilead’s fourth-quarter results statement is a line revealing it has abandoned an anti-BCMA cell therapy for multiple myeloma, part of its $12 billion acquisition of Kite Pharma.

The failed KITE-585 program and other costs associated with the acquisition resulted in a whopping $820 million impairment charge in the quarter and add to analyst speculation that with sales of approved CAR-T Yescarta still disappointing, Gilead may have to write down the value of the Kite deal entirely, according to a Bloomberg report.

Gilead’s decision to drop the KITE-585 CAR-T program reflects the increasing competition in the anti-BCMA category and doesn’t come out of the blue. The company said at the J.P. Morgan conference (JPM) last month that it would only press ahead with development of KITE-585 if its profile was very compelling.

https://www.fiercebiotech.com/biotech/gilead-drops-anti-bcma-car-t-from-kite-takes-820m-charge

Yescarta Projections

Street sees sales rising to $2.3 billion by 2025

Robert W. Baird & Co. analyst Brian Skorney says Gilead may have to write down the deal, which the company values at $11.9 billion. That means lowering the projections on its balance sheet, if the multi billion-dollar sales Wall Street expects don’t materialize. The long-time bull cut his rating on the stock to neutral in July following the management exodus.

UPDATED on 1/23/2018

Two CARTs, Two Charts: Dissecting Returns From T-Cell Therapy M&A

Bruce Booth

1/22/2018 Celgene finalized its acquisition of Juno Therapeutics for $9B, only a few short months after Gilead bought Kite Pharma for $11.9B.

It’s also clear that public investors did quite well in these deals – unlike some outcomes, both private and public investors can only be happy with these deals. Kite’s IPO investors made over a whopping 10x, and Juno’s nearly a 3.6x (in 3 years, so still a very strong public market return). Even the follow-on financing participants made handsome returns: both Kite’s and Juno’s follow-on financings about 4-6 months prior to acquisition delivered a 2x return in a short period. What’s clear is that participating at any point only these price curves was a positive for investors. Obviously that doesn’t always happen, but great to see when it does.

A final takeaway is that there is “no one size fits all” for how to build business models that can work in biotech these days, even to get to similar product and patient outcomes. While Kite and Juno have remarkably similar products, similar platforms, and similar overall acquisition valuations, the stories were built quite differently when it comes to financing their growth.

https://www.forbes.com/sites/brucebooth/2018/01/23/two-carts-two-charts-dissecting-returns-from-t-cell-therapy-ma/#23f0b7a2459e

UPDATED on 10/18/2017

Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017.

Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy

— Manufacturing Success Rate of 99 Percent in ZUMA-1 Pivotal Trial with a Median 17 Day Turnaround Time —

CAR T therapy is a breakthrough in hematologic cancer treatment in which a patient’s own T cells are engineered to seek and destroy cancer cells. CAR T therapy is manufactured specifically for each individual patient.

“The FDA approval of Yescarta is a landmark for patients with relapsed or refractory large B-cell lymphoma. This approval would not have been possible without the courageous commitment of patients and clinicians, as well as the ongoing dedication of Kite’s employees,” said Arie Belldegrun, MD, FACS, Founder of Kite. “We must also recognize the FDA for their ability to embrace and support transformational new technologies that treat life-threatening illnesses. We believe this is only the beginning for CAR T therapies.”

“Today is an important day for patients with relapsed or refractory large B-cell lymphoma who have run out of options and have been waiting for new treatments that may help them in their fight against cancer,” said John Milligan, PhD, President and Chief Executive Officer of Gilead Sciences. “With the combined innovation, talent and drive of the Kite and Gilead teams, we will rapidly advance cell therapy research and aim to bring new options to patients with many other types of cancer.”

The list price of Yescarta in the United States is $373,000.

Yescarta has been granted Priority Medicines (PRIME) regulatory support for DLBCL in the European Union. A Marketing Authorization Application (MAA) for axicabtagene ciloleucel is currently under review with the European Medicines Agency (EMA) and potential approval is expected in the first half of 2018.

Yescarta (axicabtagene ciloleucel) Pivotal Trial Results

The approval of Yescarta is supported by data from the ZUMA-1 pivotal trial. In this study, 72 percent of patients treated with a single infusion of Yescarta (n=101) responded to therapy (overall response rate) including 51 percent of patients who had no detectable cancer remaining (complete remission; 95% CI: 41, 62). At a median follow-up of 7.9 months, patients who had achieved a complete remission had not reached the estimated median duration of response (95% CI: 8.1 months, not estimable [NE]).

In the study, 13 percent of patients experienced grade 3 or higher cytokine release syndrome (CRS) and 31 percent experienced neurologic toxicities. The most common (≥ 10%) Grade 3 or higher reactions include febrile neutropenia, fever, CRS, encephalopathy, infections-pathogen unspecified, hypotension, hypoxia and lung infections. Serious adverse reactions occurred in 52% of patients and included CRS, neurologic toxicity, prolonged cytopenias (including neutropenia, thrombocytopenia and anemia), and serious infections. Fatal cases of CRS and neurologic toxicity occurred. FDA approved Yescarta with a Risk Evaluation and Mitigation Strategy.

Yescarta Indication

Yescarta is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL), accounting for three out of every five cases. In the United States each year, there are approximately 7,500 patients with refractory DLBCL who are eligible for CAR T therapy. Historically, when treated with the current standard of care, patients with refractory large B-cell lymphoma had a median overall survival of approximately six months, with only seven percent attaining a complete response. Currently, patients with large B-cell lymphoma in second or later lines of therapy have poor outcomes and greater unmet need, since nearly half of them either do not respond or relapse shortly after transplant.

“With CAR T therapy, we are reengineering a patient’s own immune system to detect and kill cancer cells, and the results have been impressive,” said Frederick L. Locke, MD, ZUMA-1 Co-Lead Investigator and Vice Chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center in Tampa, Florida. “Many of the patients that received CAR T therapy had already relapsed several times with traditional treatments such as chemotherapy or hematopoietic stem cell transplant. Now, thanks to this new therapy many patients are in remission for months.”

“This therapy is a new option for patients with relapsed or refractory large B-cell lymphoma who have run out of treatment options and face a dire prognosis,” said Louis J. DeGennaro, PhD, President and Chief Executive Officer of The Leukemia & Lymphoma Society (LLS). “Early on, LLS recognized the potential of CAR T therapy and we are proud to be part of making this historic approval possible.”

“Engineered cell therapies like Yescarta represent the potential for a changing treatment paradigm for cancer patients,” said David Chang, MD, PhD, Worldwide Head of Research and Development and Chief Medical Officer at Kite. “Together, Gilead and Kite will accelerate studies of CAR T therapy in multiple blood cancers and advance other cell therapy approaches for solid tumors, with the goal of helping patients with diverse cancers benefit from this new era of personalized cancer therapy.”

http://www.businesswire.com/news/home/20171018006639/en/Kite%E2%80%99s-Yescarta%E2%84%A2-Axicabtagene-Ciloleucel-CAR-Therapy-Approved

This article has the following structure:

  • ABOUT Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent)
  • ABOUT Gilead’s $12 billion buy of Kite Pharma
  • ABOUT  the Drug Development process and the COMMERCIALIZATION GENIUS of Arie Belldegrun – Interviewed by Globes
  • ABOUT the Perspective of Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) following the Gilead’s $12 billion buy of Kite Pharma – Interviewed by Globes
  • ABOUT the Economic significance of Kite Pharma Acquisition for the Venture Capital Investment in Biotech in Israel
  • Key Opinion Leader’s View: Aviva Lev-Ari, PhD, RN
  1. I agree with Prof. Zelig Eshhar that this Case in Point is “one more invention, or parts of an invention, came from an Israeli laboratory (at the Weizmann Institute in this case) and fell into foreign hands. It is another enormous missed opportunity in the field of biomedicine and ethical drugs.”
  2. I agree with Prof. Zelig Eshhar that this Case in Point should have been a TEVA commercialization effort. It is a regrettable reality that the development and the manufacturing will not benefit the State of Israel, home of the Weitzman Institute where the Patentable invention took place by Prof. Zelig Eshhar.
  3. It is to be acknowledged that for CAR-T – the process of treatment using the drug – personalized genetic engineering of each patient’s cells – a grafting process with no precedent in the pharmaceutical industry (Juno has related process) – is bringing to the Oncology arena a NOVEL treatment for hematological malignancies cancer patients
  4. I agree with Prof. Zelig Eshhar that the Barriers in the pharmaceutical industry are especially high. Developing ethical drugs is a process requiring huge amounts of time, patience, money, and failures. It is exactly, therefore, all need to acknowledge that the Drug Development process and the COMMERCIALIZATION GENIUS of Arie Belldegrun is inseparable from the breakthrough invention of Prof. Zelig Eshhar to develop the drug from the Lab bench to the FDA accelerated process of Drug approval.
  5. The Biotech industry in Israel needs to develop more MDs, PhDs with the level of training of Arie Belldegrun and with his entrepreneur acumen, keenness and depth of perception, discernment, discrimination especially in practical aspects of Translation Medicine, Clinical Research, Clinical Trial Design and abilities to engage in innovating the FDA processes.
  6. The Biotech industry in US needs to develop more MDs, PhDs with the level of training of Prof. Zelig Eshhar to carry the scientific gravitas and the creativity to become inventors of novel drugs.

ABOUT Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent)

Pioneers of Cancer Cell Therapy:  Turbocharging the Immune System to Battle Cancer Cells — Success in Hematological Cancers vs. Solid Tumors

Curator: Aviva Lev-Ari, PhD, RN

Pioneers of Cancer Cell Therapy: Turbocharging the Immune System to Battle Cancer Cells — Success in Hematological Cancers vs. Solid Tumors

ABOUT Gilead’s $12 billion buy of Kite Pharma

FDA has approved the world’s first CAR-T therapy, Novartis for Kymriah (tisagenlecleucel) and Gilead’s $12 billion buy of Kite Pharma, no approved drug and Canakinumab for Lung Cancer (may be?)

Curator: Aviva Lev-Ari, PhD, RN

FDA has approved the world’s first CAR-T therapy, Novartis for Kymriah (tisagenlecleucel) and Gilead’s $12 billion buy of Kite Pharma, no approved drug and Canakinumab for Lung Cancer (may be?)

ABOUT  the Drug Development process and the COMMERCIALIZATION GENIUS of Arie Belldegrun – Interviewed by Globes

“Chemotherapy will become just a bad memory”

More energetic than ever, Arie Belldegrun talks to “Globes” about Kite Pharma’s remarkable journey and the future of cancer treatment.

http://www.globes.co.il/en/article-chemotherapy-will-become-just-a-bad-memory-1001206978

ABOUT the Perspective of Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) following the Gilead’s $12 billion buy of Kite Pharma – Interviewed by Globes

Kite Pharma was a $12b missed opportunity for Israel – Interview with Professor Zelig Eshhar

Some Israeli media headlines depicted Kite as an Israeli exit. But it is a US company that does no business in Israel and has no employees here.

Professor Zelig Eshhar is the man who registered the patent on the cancer treatment drug developed by Kite Pharma, recently acquired by Gilead for $11.9 billion.

“Globes”: Do you believe that any party in Israel could have financed the product and brought it where it is today?

Eshhar: “On the one hand, yes. The level of investment in the product before it reached Nasdaq was something that an Israeli concern could certainly have financed. On the other hand, Kite Pharma founder Professor Arie Belldegrun, with his energy and connections, brought it to a completely different place (Eshhar previously tried to interest various concerns in Israel in financing the drug, but all of them told him that it was too early, or that the product was not effective enough, E.T.).

Was the development already in its final form in the 1980s?

“Almost. I went to the National Institutes of Health (NIH), where I met for the first time Professor Steven Rosenberg, who later became the first doctor to conduct clinical trials with the technology. Rosenberg heard about my technology, and offered me exceptional conditions. We set up a team there, and had the best of everything. I only wish I had it now.”

They say that Belldegrun didn’t want the product at first. Today, he’s devoting all his efforts to it.

“When Arie founded Cougar Biotechnology, which developed a drug for prostate cancer, and was eventually sold to Johnson & Johnson for $1 billion, I contacted him and offered him the technology, but he was busy with Cougar’s product, and maybe didn’t think that he had enough capital for such a production. Only after he sold Cougar did he get back to me with an offer to buy the rights to my patent. At that time (2009-2010), the technology was already arousing great interest, and there were negotiations with several large companies.” (from an April 2015 “Globes” interview with Eshhar, who was awarded the Israel Prize).

Israelis can be very provincial. In at least some of the media headlines, Kite Pharma was portrayed as a “huge Israeli exit,” and the impression was given that it was an Israeli company. The truth is very different. Kite Pharma is not an Israeli company; it is a 100% US company. It does no business in Israel; its nearly $12 billion exit has no significance whatsoever for the Israeli economy, and will contribute nothing to it: no jobs, and the tax contribution will be marginal, and certainly not on the scale of Mobileye, for example. Let me say it again: Kite Pharma does not have even one employee in Israel (and has no reason to employ anyone here), and certainly does not pay taxes in Israel. There are no Israelis on the company’s management team or board of directors. This is a US company for all intents and purposes. The word “Israel” appears exactly once in the company’s full documents – where registration of the company’s patents is concerned. The fact that every story about the company mentions the small holdings of several Israeli financial institutions in it is a bad joke. Everyone should remember that Israeli financial institutions are of course entitled to invest in any foreign share, such as Google, Amazon, Facebook, Apple Computers, and so forth. Kite Pharma is one of those foreign shares, and nothing more.

Of course, there is cause for pride in the fact that Eshhar, owner of the patent for Kite Pharma’s drug is “one of ours,” i.e. an Israeli researcher at the Weizmann Institute of Science. Another source of pride is Kite Pharma founder and CEO Arie Belldegrun, a graduate of the Hebrew University Medical School who did his post-doctorate at the Weizmann Institute, where he met Eshhar, and Kite Pharma later bought his patent for the cancer drug. Belldegrun was also a director at Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) until recently, resigning at the peak of that company’s crisis. Beyond this Israeli connection, however, the Kite Pharma exit has no great significance for Israel. All it means is that one more invention, or parts of an invention, came from an Israeli laboratory (at the Weizmann Institute in this case) and fell into foreign hands. It is another enormous missed opportunity in the field of biomedicine and ethical drugs.

It is necessary to realize that while Belldegrun is indeed a big biomedical brain with many achievements in the field, he is a brain that has left Israel, and we all have to ask ourselves why he left, why Kite Pharma is not an Israeli company, and why its (as yet non-existent) product was not developed in Israel and will not be manufactured there. The headline in Israel for the Kite Pharma exit should ask why Israel lost out on it, even though the patent came from Israeli laboratories, albeit with US cooperation.

Belldegrun is likely to keep his experiences on the Teva board of directors to himself. Of all the directors in the company, what he has to say is the most interesting, but he is unlikely to divulge what happened there with the inflated deal with Allergan, and exactly what he said at the board of directors meeting that approved the deal that led Teva into its current major crisis. The Kite Pharma exit and his other exits only highlight the lost opportunity. Kite Pharma, still without a product and without approval for a product, was sold for $11.9 billion in cash. Teva yesterday hit another low point, with a market cap of $16 billion. It is simply inconceivable: a company with an enormous potential, but no product, is worth three quarters of a huge veteran company with at least dozens of products, including products in the ethical drug sector. Kite Pharma is actually one of the indirect reasons for Teva’s decline – for the fact that Teva, which could have been a hothouse for developments like Copaxone, chose a huge inflated gamble on the generics market – a gamble that is now jeopardizing Teva’s future and very existence.

It is true that developing drugs is a very long process, requires huge amounts of capital, and involves many failures, but Teva decided to neglect it, and when a major company like Teva neglects Israeli developments, there are enough competitors in the pharma industry ready to turn Israeli research into gold. Kite Pharma is one example of this research.

The Weizmann Institute is a fruitful source of biomedical research. According to previous estimates published in “Globes,” the Weizmann Institute gets NIS 1 billion each year in royalties on medical and other developments, amounting to half of its budget. Directly and indirectly, the Weizmann Institute, together with other universities in Israel, is responsible for tens of billions of pharmaceutical sales. Only a few billions of this, however, results from drugs developed in Israel, like Copaxone, and far less than that is also made in Israel. The reports by Yeda R&D Company Ltd., the technology transfer arm of the Weizmann Institute of Science, are top secret, and there is a good reason for that. Exposing them will only highlight the scale of the missed opportunities. Instead of these inventions providing a base for a major pharmaceutical industry here, the commercialization companies are benefiting only the inventors and the Weizmann Institute itself (that is certainly natural and legitimate, and they are entitled to it), even though the research infrastructure from which they sprung is Israeli know-how, as in the case of Eshhar.

Barriers in the pharmaceutical industry are especially high. Developing ethical drugs is a process requiring huge amounts of time, patience, money, and failures. When it succeeds, however, the profit is enormous – for the industry, the employees, and the state (provided that some tax is paid). For example, Pfizer’s peak sales of Lipitor, a very popular drug for reducing cholesterol and fat in the bloodstream, reached $11 billion, and its profit on the drug was $9 billion, before competition from a generic version began. In addition to money, a great deal of experience and marketing power is required, and that is the reason why most developments wind up in the hands of major companies like Pfizer, Merck, and others at some stage. After all these qualifying statements, everyone who celebrated Kite Pharma’s exit should weep over it – it is another part of the sale of Israeli know-how overseas for a mess of pottage. Instead of consolidating a splendid pharma industry here, Israel is selling the brains with their know-how to foreigners. More than anything else, Teva’s decline and the Kite Pharma exit epitomize this sad and dangerous trend.

Published by Globes [online], Israel Business News – www.globes-online.com – on August 30, 2017

© Copyright of Globes Publisher Itonut (1983) Ltd. 2017

http://www.globes.co.il/en/article-kite-pharma-the-huge-exit-that-israel-missed-1001203173

ABOUT the Economic significance of Kite Pharma Acquisition for the Venture Capital Investment in Biotech in Israel

Israeli investors profit from $11.9b Kite acquisition

Pontifax fund and Israeli institutional investors will profit from the US personalized cancer drug company’s huge sale.  Part of the technology was developed at the Weizmann Institute

Pharmaceutical company Gilead Sciences Inc. has announced that it will acquire US company Kite Pharma Inc., developer of personalized cancer treatment drugs, at a company value of $11.9 billion. This is one of the biggest ever acquisitions of a company whose products have not yet been approved for marketing. The company value for the acquisition reflects a 29% premium on the market price.

Kite Pharma has developed a new method for genetically engineering immune system cells, so that they will make a focused attack on the malignant tumor. The company was founded in the US by Israeli-American Professor Arie Belldegrun, who already has two exits to his credit. He is also a former director at Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) (whose current value is not much more than the value at which Kite Pharma, a company with no products approved for marketing yet, is being acquired).

A significant part of the technology on which the product is based was developed by Professor Zelig Eshhar of the Weizmann Institute of Science.

The main Israeli beneficiary of the acquisition is the Pontifax fund, which invested $3.8 million in Kite Pharma at an early stage, but which distributed Kite Pharma shares worth $120 million to its investors. Among the investors in Pontifax that received shares in Kite Pharma are Menorah Mivtachim Holdings Ltd. (TASE: MORA) (which also bought shares on the market, and whose stake in the company is now worth over $100 million), The Phoenix Holdings Ltd. (TASE: PHOE1;PHOE5), Altshuler Shaham Ltd., Meitav Dash Investments Ltd. (TASE:MTDS), Harel Insurance Investments and Financial Services Ltd. (TASE: HARL), and Mori Arkin.

Kite Pharma is waiting for marketing approval of its first product, following a successful trial on 100 patients on a very abbreviated track for innovative cancer products. The product was initially designed for treatment of blood cancer, but it is now hoped that its use can later be expanded to treatment of other types of cancer. Gilead is making a big gamble, first of all that the US Food and Drug Administration (FDA) will fulfill its commitment to approve the product, even though the development plan it devised, together with the company, was very short and limited. The second gamble involves the process of treatment using the drug – personalized genetic engineering of each patient’s cells – a grafting process with no precedent in the pharmaceutical industry.

Speaking about the talks to sell Kite, Prof. Arie Belldegrun told “Globes.” “We handled like in the IDF 669 unit. Nobody knew anything. Nobody heard anything. We held meetings in places where nobody would see us. And before we announced it only five employees knew about it.”

Published by Globes [online], Israel Business News – www.globes-online.com – on August 28, 2017

© Copyright of Globes Publisher Itonut (1983) Ltd. 2017

http://www.globes.co.il/en/article-israeli-investors-profit-from-119b-kite-acquisition-1001202841

Other related articles published in this Open Access Online Scientific Journal include the following: 

Curators: Stephen J Williams, PhD and Aviva Lev-Ari, PhD, RN

  • Cancer Biology & Genomics for Disease Diagnosis, on Amazon since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

  • Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2) – on Amazon since 5/18/2017

http://www.amazon.com/dp/B071VQ6YYK

Read Full Post »

« Newer Posts - Older Posts »